Trading Analysis Report: NKE¶

Analysis date: 2026-10-14
Rating: Underweight
Generated: 2026-10-15 00:28:11
TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-sonnet-5-5
Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 35.30 Price As Of: 2026-10-14

NKE (NIKE, Inc.): Technical Report as of 2026-10-14¶

NKE trades on NYQ in USD. The tools I used contain no news or earnings data. I don't attribute any move to a specific catalyst, and I'm reporting evidence rather than making the trade decision.

1. Data verification¶

The verified snapshot and the OHLCV feed agree on the 2026-10-14 bar: open 35.45, high 35.56, low 34.71, close 35.30, volume 19,377,400.
The RSI (43.82), MACD histogram (0.19) and ATR (1.06) from the indicator calls match the snapshot values. I found no discrepancies.
The daily Z-score of -0.06 is consistent with the snapshot's close (35.30) against its Bollinger midline (35.34).

Indicators chosen (8 pulled, plus snapshot values): - Trend: supertrend (three timeframes) and adx. The snapshot supplies the 10 EMA, 50 SMA and 200 SMA. - Momentum: rsi and macdh. - Volatility: atr. The snapshot supplies the Bollinger bands. - Volume: obv. - Exhaustion and stretch: td_9 and z_score.

I skipped stochrsi and the KDJ lines because they duplicate rsi. I skipped mfi because obv covers volume. I skipped pdi and mdi because of the 8-indicator cap, so ADX tells me trend strength but not direction. SuperTrend supplies the direction.

2. Price structure¶

Long decline: The close fell from 72.19 on 2025-10-02 to 35.30 on 2026-10-14, a drop of about 51%.
Gap-down events: The decline came largely in discrete, heavy-volume gaps.
2025-12-18 to 12-19: the close went from 63.94 to 57.20 (about -10.5%) on 108.7M shares.
2026-03-31 to 04-01: the close went from 51.80 to 43.77 (about -15.5%) on 114.2M shares.
2026-10-01 and 10-02: volume was 112.4M and 142.7M, the 3^rd and 1^st highest in the sample. On 10-02 the stock opened at 32.55, about 7.4% below the prior close of 35.15. It made an intraday low of 31.97 and closed at 33.87.
Prior base broken: From April to July the stock held a rough 40–46 range. Its lowest closes were 40.32 on 06-26 and 40.56 on 07-23. It broke below that on 2026-08-17 (close 38.68, volume 58.7M). It then drifted to a 35.5–36.4 closing cluster from 09-18 to 09-29 before the 10-02 gap.
Current action: Since the 10-02 close of 33.87, price has risen about 4.2%. It has gone sideways for three sessions at 35.30–35.35 (10-12 to 10-14). The 10-02 gap zone (10-02 high 33.97 to 10-01 low 35.02) has been traded back through.

3. Trend¶

Moving averages are bearishly stacked. The 10 EMA is 35.09, the 50 SMA is 37.59 and the 200 SMA is 46.87, so price is above only the 10 EMA. Price is about 6.1% below the 50 SMA and about 24.7% below the 200 SMA. The 50 SMA sitting below the 200 SMA is a standing long-term bearish configuration.
SuperTrend is down on all three tiers.
Weekly (primary): DOWN, stop 42.88, close 17.68% below it.
Monthly: DOWN, stop 59.28, close 40.46% below it.
Daily: DOWN, stop 36.38, close 2.98% below it.
Only the daily line is within reach. A close above 36.38 would flip the daily tier, about 3.1% above the current price. The weekly flip needs a close above 42.88, about 21.5% higher. These stops trail and will move as the trend develops.
ADX shows trend strength fading.
It peaked at 36.71 on 10-07 and has fallen every session since: 35.05, 32.57, 29.29, 24.19, then 22.36 on 10-14.
That is just under the 25 "tradable trend" threshold and not yet in the below-20 range regime.
The fall reflects the gap impulse being absorbed as price stabilizes. It doesn't signal a reversal. A trend-following signal taken now would be in a weaker-trend environment than it was a week ago.

4. Momentum¶

RSI is 43.82. It hit 28.49 on 10-02 and 29.41 on 10-05, both below 30, and has recovered about 15 points. It is still below 50 and has not closed above 44.2 in the 30-day window. A reading back above 50 would be the first sign of a regime change.
MACD has turned up but remains in negative territory.
The MACD line is -0.74 and the signal is -0.93, so the line is above the signal.
The histogram turned positive on 10-08 (+0.014) and has risen for eight straight sessions to +0.192.
The increments are shrinking (+0.046 on 10-13, then +0.027 on 10-14), so upward momentum is decelerating.
A similar positive stretch ran from 09-24 to 10-01, with a peak of +0.093 on 09-29. It reversed when the 10-02 gap hit. This is an observation and not evidence that the pattern repeats.
With the MACD line below zero, this is a counter-trend bounce signal.

5. Volatility¶

Bollinger bands:
The midline is 35.34, the upper band 36.87 and the lower band 33.82.
Price sits at the midline, with the upper band about 4.5% above and the lower band about 4.2% below. Band width is about 8.6% of the midline.
The lower band (33.82) lines up with the 10-02 closing low (33.87), which gives that area added significance as a reference.
ATR is 1.06, or about 3.0% of price. It peaked at 1.15 on 10-05 and is decaying, but it is still above the 0.96–0.99 level it held in mid and late September. For sizing, 1× ATR is about 1.06 and 2× is about 2.11. A 2× ATR distance below the close is about 33.19, which sits under the 10-02 closing low (33.87) and above the 10-02 intraday low (31.97).

6. Volume¶

OBV is not confirming the bounce.
It stands at about -1.631B, against -1.273B on 09-14.
It was about -1.634B on 10-05 and is about -1.631B now. Over that span price rose from 33.96 to 35.30 (about 3.9%) while OBV stayed flat.
OBV fell on 10-13 and 10-14 even though price barely moved (-0.02 and -0.03). OBV counts any down close as a full down-volume day, so these two small declines overstate the distribution.
The rebound is on fading volume. Daily volume ran 69.6M, 50.1M, 37.6M, 43.8M, 27.5M, 23.7M, 30.2M, then 19.4M on 10-14. That is the lowest since 2026-08-24 (18.8M). It can be read as selling pressure drying up or as weak buying interest. Taken with OBV, it leans toward a relief bounce and not accumulation.

7. Exhaustion and stretch¶

TD-9 shows opposing signals across timeframes.
Weekly: +9, a completed buy setup.
Monthly: +9, a completed buy setup.
Daily: -5, a sell setup at 5 of 9.
The weekly and monthly 9s flag downside exhaustion on the highest tiers. That is a reversal watch and not a confirmed turn, because setups can extend and the tool gives no confirmation signal.
The current week and month are still in progress, so these 9s may be provisional until the bars close.
The daily count rises with each close above the close four sessions earlier. The next closes would need to beat 34.71, 35.35, 35.33 and 35.30 in order, so the earliest daily 9 is about 2026-10-20.
Z-scores show no statistical stretch.
Weekly: -1.30. Monthly: -1.56. Daily: -0.06.
None reaches the |2| flag. The daily reading is at fair value, so the oversold condition of 10-02 to 10-05 has been largely worked off. The weekly and monthly readings show the larger decline is still somewhat extended.

8. Synthesis¶

Where the indicators agree (bearish): - All three SuperTrend tiers are down. - Price is below the 50 and 200 SMA. - OBV is not confirming the bounce. - The MACD line is below zero. - RSI is below 50.

Where they offer a counterpoint (stabilization or relief): - The MACD histogram has risen for eight sessions and the MACD line is above its signal. - RSI has bounced off sub-30 readings. - Weekly and monthly TD-9 have completed buy setups. - The gap has been traded back through. - Price is at the Bollinger midline and above the 10 EMA. - ADX is fading, so downward trend strength is easing.

Reading: The primary trend is bearish on every higher-tier measure. The last eight sessions look like a tentative stabilization or relief bounce that volume and OBV don't yet support. The tool rule is to weight higher tiers above lower ones. The weekly and monthly SuperTrend direction (down) therefore outweighs the daily MACD improvement. The weekly and monthly TD-9 completions are the main counterweight and need confirmation.

9. Reference levels (all from tool output)¶

Overhead: - 36.38: daily SuperTrend stop, just under the 09-28 close of 36.39 and inside the 35.51–36.39 closing cluster of 09-18 to 09-29. - 36.87: upper Bollinger band. - 37.59: 50 SMA. - 38.10–38.77: early-September closes (09-03 and 09-08). - About 40: June–August lows and the 08-17 breakdown area. - 42.88: weekly SuperTrend stop. - 46.87: 200 SMA.

Below: - 35.09: 10 EMA. - 34.71: today's low. - 34.10: 10-09 low. - 33.87: 10-02 closing low. - 33.82: lower Bollinger band. - 31.97: 10-02 intraday low.

10. What to watch¶

Constructive confirmation: A close above 36.38, then 36.87, would flip the daily SuperTrend and clear the upper band. Additional confirmation would be RSI above 50, OBV making higher readings, and ADX re-expanding.
Bearish continuation: A rejection near 36.38–36.87 followed by a close below 34.10, then 33.87–33.82, would put the 10-02 intraday low (31.97) back in play. A fall in ADX below 20 with a flat MACD would suggest a range and not a trend.
Event risk: The big declines were gap-driven. Stops placed by ATR alone may not hold through a gap, since 10-02 opened about 7% below the prior close.
Dividend: The data shows $0.41 ex-dividends on 2025-12-01, 2026-03-02, 2026-06-01 and 2026-09-01. That annualizes to $1.64, about 4.6% of the current price.

Summary table¶

Category	Indicator	Reading (2026-10-14)	Interpretation
Price	Close / Volume	35.30 / 19.38M	Three-day flat consolidation. Volume is the lowest since 08-24.
Trend	10 EMA / 50 SMA / 200 SMA	35.09 / 37.59 / 46.87	Bearish stack. Price is 6.1% below the 50 SMA and 24.7% below the 200 SMA.
Trend	SuperTrend (W / M / D)	Down / Down / Down	Stops 42.88 / 59.28 / 36.38. Only the daily line is near (3.1% away).
Trend strength	ADX	22.36 (peak 36.71 on 10-07)	Fading trend strength. Direction is not shown by ADX.
Momentum	RSI	43.82 (low 28.49 on 10-02)	Recovered from oversold but still below 50.
Momentum	MACD / Signal / Hist	-0.74 / -0.93 / +0.19	Bullish cross below zero. Histogram rising for 8 sessions but the increments are shrinking.
Volatility	Bollinger (L / M / U)	33.82 / 35.34 / 36.87	Price at the midline. Band width about 8.6%.
Volatility	ATR	1.06 (about 3.0% of price)	Decaying from 1.15 on 10-05 but above September's level.
Volume	OBV	About -1.631B	Flat since 10-05 while price rose about 3.9%. The bounce isn't confirmed.
Exhaustion	TD-9 (W / M / D)	+9 / +9 / -5	Weekly and monthly buy setups are complete (a reversal watch, possibly provisional). Daily sell setup at 5 of 9.
Stretch	Z-score (W / M / D)	-1.30 / -1.56 / -0.06	No
Key levels	Overhead / below	36.38, 36.87, 37.59 / 34.10, 33.87, 33.82, 31.97	Reference levels from tool output only.
Overall	Higher-tier bias	Bearish primary trend with a tentative relief bounce	The decision is left to the next agent.

Sentiment Analyst¶

Overall Sentiment: Mildly Bearish (Score: 3.8/10) Confidence: Low

Scope and data quality (read first). This read covers NKE (NIKE, Inc., NYQ) for 2026-10-07 to 2026-10-14. Three limits cap confidence at LOW. (1) Reddit was disabled by config, so there is no community-forum evidence. (2) The StockTwits sample is tiny (18 messages), and 17 of the 18 come from one account (@MR_TIMING), who says he holds puts. (3) The news feed has headlines only, with no article bodies, so the size and rationale of analyst actions cannot be verified from this evidence.

1. Source-by-source breakdown

News (Yahoo Finance, 19 headlines; institutional framing). About 12 headlines are directly about NKE. Roughly 4 are sector or peer items (JD Sports, Lululemon, global sports retailing market report). Roughly 3 are unrelated filler (BHG Financial workplace award, Valuedynamx/Tesco Clubcard, startup hiring). The NKE-specific flow leans negative: - Sell-side: 'HSBC Adjusts Nike Price Target to $34 From $40' (a cut of about 15%) and 'BofA Turns Bearish on Nike: What's Behind the Downgrade?'. These are the only hard events in the window, and both are negative. The HSBC target sits roughly at the ~$34-35 price level implied by StockTwits chatter. That level is inferred, not verified, and would suggest little upside in HSBC's framework. - Fundamental narrative: 'Nike's Reset Isn't Working Yet as Revenue Declines Deepen' (GuruFocus) and 'Nike has a long road ahead to win customers back' (TheStreet). Both point to a turnaround that has not yet shown up in revenue. - Drawdown framing: 'Nike Is Down 80% From Its High. Here's the Only Number That Matters.' and 'These S&P 500 Stocks Are Down More Than 80% From Their All-Time Highs. Could They Be Good Contrarian Buys?' (Motley Fool), plus MarketBeat's '3 Stocks Chopped in Half: Why These Drops May Be Structural, Not a Dip'. The Motley Fool pieces ask whether the drawdown is a contrarian opportunity. The MarketBeat title argues the declines may be structural. I cannot confirm from titles alone that Nike is among the MarketBeat stocks. - Offsetting positives: 'Vans Turnaround Has More Than a Few Green Shoots' (Footwear News) and 'Yue Yuen's Footwear Shipments Show Positive Momentum in September' (Footwear News). Yue Yuen is a major footwear manufacturer, so its shipments are a supplier-side read-through to demand and order flow. The article body is not provided, so I cannot confirm how much of its volume is Nike. - Neutral or analytical: Zacks 'CRI vs. NKE: Which Stock Is the Better Value Option?', Zacks 'NIKE's Digital Transformation: Competitive Edge or Cost Burden?', and a Zacks earnings preview listing Nike alongside JPMorgan, Citigroup, Pepsi and Micron. The evidence does not say when Nike's next report is or what the preview concludes, so I treat it as an unverified catalyst. - Net news read: moderately bearish. Two negative analyst actions and several skeptical turnaround headlines outweigh two modestly positive operational items.

StockTwits (18 most-recent messages, all timestamped 2026-10-14 between ~22:09Z and 23:55Z). The tagged split is Bullish 1 (6%), Bearish 13 (72%), Unlabeled 4. The raw ratio is lopsided, but it should not be read as broad retail consensus: - Concentration: 17 of 18 messages, including all 13 Bearish tags, come from @MR_TIMING. The only other voice, @DFWxplorer, is the single Bullish post ('Hung tough on a very rough day!'). Effective independent sample is about 2 users. - Conflict of interest: @MR_TIMING says he is holding puts and boasts of a ~$6,500 gain ('up 45 percent on 15,000'). His calls for '29 by Friday', '5-10 percent down by Friday', and 'puts will pay' read as position-talking, not independent analysis. - Level-setting: he says 'you had to hold 35.20 and well you failed' and 'you will never see 36 again nor 35 maybe not 34', which implies NKE was trading around ~$34-35 into the close. This is user-claimed and unverified. - Contradictory cues: he complains 'while markets red why not here hardly any red', and DFWxplorer says NKE 'hung tough on a very rough day'. Both suggest NKE showed relative resilience on a weak market day. One of his unlabeled posts even anticipates shorts closing at '33.50-34.50' and letting it rise. - Net social read: bearish in tone, but low-information, single-voice, and sampled over a ~2-hour window instead of the full 7 days.

Reddit (r/wallstreetbets, r/stocks, r/investing). Not available; the source was disabled by config. No inference about Reddit sentiment can be made.

2. Cross-source divergences and alignments - Alignment: news and StockTwits both lean bearish, but StockTwits adds little independent confirmation because it is essentially one account. The institutional signal (BofA, HSBC, 'reset isn't working') is the more credible bearish evidence. - Divergence (operations vs. sell-side): Vans 'green shoots' and Yue Yuen's positive September shipments point to operational stabilization or improving order flow. They sit against analyst downgrades and headlines about deepening revenue declines. This could indicate the data lags the recovery, or that sell-side caution is aimed at margins, valuation, or the pace of the turnaround. The evidence does not say which. - Divergence (price action vs. rhetoric): the loudest bear says NKE is not falling with a red market, which is a mild relative-strength signal that contradicts the 'crash' calls. - Missing leg: with no Reddit data, there is no check on whether broader retail sentiment matches the StockTwits read.

3. Dominant narrative themes 1. The turnaround is unproven: the reset is not yet visible in revenue, and winning customers back will be a long road. 2. Sell-side capitulation or caution: the BofA bearish turn and the HSBC target cut to $34 from $40. 3. Deep drawdown, contrarian value or value trap: ~80% below the high, with the debate over cheap valuation versus structural decline. 4. Early green shoots: the Vans recovery and supplier shipment momentum. 5. Macro and market weakness: StockTwits chatter refers to a red market on 2026-10-14 and fear of further downside.

4. Catalysts and risks surfaced by the data - Downside risks: further analyst downgrades or target cuts; continued revenue declines; a broader market selloff (referenced in the posts); loss of the ~$35 area cited by the StockTwits user; a digital or transformation cost burden (Zacks framing). - Upside catalysts or offsets: Vans turnaround progress; continued positive supplier-shipment data (Yue Yuen); contrarian or value buyers attracted by the drawdown; relative resilience on down-market days; short covering, as hinted in one unlabeled post. - Unverified: the timing of Nike's next earnings event. A Zacks earnings-preview headline mentions Nike, but no date or content is in the evidence. - Caveat: this is a sentiment read, not a price call, and should be weighed against fundamentals and technicals. It does not predict future returns.

5. Summary table of key sentiment signals

Signal	Direction	Source	Supporting evidence
BofA turns bearish on Nike	Bearish	News (Insider Monkey)	Headline: 'BofA Turns Bearish on Nike: What's Behind the Downgrade?'; rationale not provided
HSBC price target cut	Bearish	News (MT Newswires)	PT to $34 from $40 (about -15%); roughly at the implied ~$34-35 price
Reset not working / revenue declines deepen	Bearish	News (GuruFocus, TheStreet)	'Reset Isn't Working Yet as Revenue Declines Deepen'; 'long road ahead to win customers back'
Drawdown ~80% from high; structural vs. dip debate	Mixed to Bearish	News (Motley Fool, MarketBeat)	Contrarian-buy framing in Motley Fool; 'may be structural, not a dip' in MarketBeat (Nike inclusion unverified)
Vans turnaround green shoots	Mildly Bullish	News (Footwear News)	'More Than a Few Green Shoots'; details not provided
Yue Yuen September shipments up	Mildly Bullish	News (Footwear News)	'Positive Momentum in September'; Nike share of volume unverified
Retail tagged split	Bearish (low reliability)	StockTwits	1 Bullish (6%) / 13 Bearish (72%) / 4 unlabeled, 18 msgs; 17 from a single put-holder
Relative strength on a red market day	Mildly Bullish	StockTwits	@DFWxplorer: 'Hung tough on a very rough day!'; the bear concedes 'hardly any red'
Reddit	No data	Reddit	Disabled by config
Next earnings event	Unknown	News (Zacks preview)	Nike named in an earnings-preview headline; date and content not in evidence

News Analyst¶

NKE (NIKE, Inc.): News and Macro Report, week ending 2026-10-14¶

1. Bottom line¶

The macro backdrop is hostile to NKE. Inflation is re-accelerating, the Fed appears to be hiking again, and the 10-year Treasury yield is above 5.2%. Oil is about $103. On the company side, the week's headlines skew negative: a BofA downgrade, an HSBC price-target cut, and "reset isn't working yet" coverage. The one clear positive is a supplier read-through from Yue Yuen. Positioning looks washed out, but nothing I retrieved shows a fundamental catalyst. I'd call the setup bearish to neutral near term, and it is rate-sensitive and event-heavy.

Limits of the data - The news tool returned headlines and links only, with no article text or dates. I can't verify the details behind any headline, including the NKE earnings numbers. - I had no price data, so I can't say where NKE trades. - These FRED requests returned 403 errors: core PCE, core CPI, VIX, the 10Y–2Y yield curve, the 2-year yield, consumer sentiment, and retail sales. I did not estimate those values. - The Polymarket search for "Nike" returned only a Slovak soccer league ("Niké Liga"), which is irrelevant. - Polymarket had no markets matching oil prices or China trade/tariffs.

2. NKE-specific news (headline-level)¶

Negative / bearish - BofA turned bearish on Nike. The headline refers to a downgrade. The rationale wasn't retrievable. - HSBC cut its price target to $34 from $40 (about -15%). This confirms analysts are still lowering numbers. - "Nike's Reset Isn't Working Yet as Revenue Declines Deepen" (GuruFocus) and "Nike has a long road ahead to win customers back" (TheStreet) both point to continued top-line pressure. - "3 Stocks Chopped in Half: Why These Drops May Be Structural, Not a Dip" (MarketBeat) frames the decline as structural.

Neutral / contrarian - Motley Fool pieces say "Nike Is Down 80% From Its High" and list it among S&P 500 stocks down more than 80% from all-time highs as possible contrarian buys. Retail-facing coverage is now leaning toward a value or turnaround story. - Zacks ran a "CRI vs. NKE" value comparison and a piece on NIKE's digital transformation ("competitive edge or cost burden?"). - Zacks listed Nike in an earnings preview alongside JPMorgan, Citigroup, Pepsi, and Micron. That article may predate this week, and I can't confirm the timing of Nike's last report.

Positive / read-through - Yue Yuen's September footwear shipments rose. Yue Yuen is a major athletic-footwear manufacturer, so this is a supply-chain signal that orders are holding up. It is a weak but useful positive. - "Vans Turnaround Has More Than a Few Green Shoots" (Footwear News) suggests competitors' brand resets are showing progress. That is a sector read-through, and it also means competition for shelf space is improving.

Sector context: Lululemon is under scrutiny ("How Much Should This One Number Worry Lululemon Holders?"). JD Sports joined the Fashion Impact Collective. Athletic and apparel peers are all under investor scrutiny.

3. Macro backdrop (from FRED data)¶

Indicator	Latest	Context
10-yr Treasury	5.21% (Oct 13)	Peak of 5.31% on Oct 5. It was 4.72% in mid-Aug and 4.03% a year ago (+118 bp y/y).
Fed funds (effective, monthly avg)	3.75% (Sep)	Flat at 3.63–3.64% from Jan to Aug, then +12 bp in Sept.
CPI index (SA)	336.298 (Sep)	+0.65% m/m in Sept and +0.40% in Aug. It is +3.46% since Nov 2025. The 12-month change wasn't in the retrieved window.
Unemployment	4.2% (Sep)	Down from 4.5% in Nov 2025. It ticked up from 4.1% in Jul and Aug.

Interpretation - Inflation is re-accelerating. CPI fell in June (-0.42% m/m) and has since risen each month. Sept's +0.65% is the hottest print since March (+0.87%). A Bloomberg headline says hot inflation is lifting October rate-hike bets. - The Fed appears to have already hiked. The Sept effective rate jump of about 12 bp, which would fit a mid-month 25 bp move, fits that. So does Polymarket's "Another Fed rate hike" wording. This is my inference. I did not see the FOMC decision itself. - The labor market is solid. Unemployment of 4.2% supports spending volumes. Real incomes are being squeezed by about 3.5% inflation, higher mortgage rates, and gasoline. - Long rates are the main stress point. Global bond yields are surging, and France is described as on the "ugly side." Mortgage rates are at their highest level in nearly three years, with "Is 8% next?" commentary. BofA's fund manager survey says investors won't rotate from stocks to bonds until yields hit about 5.9%, so there may be more room for yields to rise.

4. Market-implied probabilities (Polymarket)¶

Event	Probability	Note
No Fed rate cuts in 2026	97%	Volume of $8.9M
Another Fed rate hike in 2026	82%	+5 pp w/w; resolves 2026-12-10
2 hikes in 2026	66%	The markets likely count total hikes in 2026, including any already done. The wording is ambiguous.
3 hikes in 2026	18%	+7.2 pp w/w
1 hike in 2026	18%	-6 pp w/w
US recession by end-2026	8%	+1 pp w/w
US–Iran ceasefire holds through Oct 31	80%	+8 pp w/w
US invades Iran before 2027	16%	$74M volume
US–Iran final nuclear deal by Dec 31	12%
US–Canada tariff-reduction deal by Dec 31	40%	Only 7% by Oct 31

The market is pricing higher-for-longer, with hikes rather than cuts. Recession odds are low, so the risk is stagflation-lite and valuation compression rather than a demand collapse.

5. Broader market and geopolitical news¶

Equities: BlackRock turned more bearish on stocks. Commentary cites "bubble-like valuations and debt crisis chatter." Tech slumped on rising oil and rebounded as AI-trade jitters eased. Banks rose on JPMorgan and Goldman earnings while chip stocks fell. Earnings season is underway.
Oil: Crude fell to about $103 after Trump said the US will not attack Iran before the midterm elections. Oil is still very elevated, which feeds inflation and squeezes consumers.
Gold: It "lost its glitter" this year, and hot inflation pushed rate-hike bets up.
Politics: The midterm elections are on Nov 3 and are a headline-risk window for tariffs and geopolitics.

6. Implications for NKE¶

Valuation and duration risk. NKE's thesis depends on a multi-year earnings recovery. That kind of stock is hurt most when the 10-year is above 5%. A move back through 5.3% would add pressure. A pullback below about 5.0% would ease it.
Cost and consumer squeeze. Oil near $103 raises freight costs and petrochemical-based materials costs. It also hurts the discretionary budgets of the lower- and middle-income buyers that athletic footwear depends on. Higher mortgage rates add to that.
Analyst momentum is negative. The BofA downgrade and HSBC's cut to $34 mean estimate revisions are still falling. Stocks rarely bottom while targets are being cut, though sentiment is already poor.
Supply-chain data is a modest offset. Yue Yuen's shipment growth and the Vans recovery suggest the category isn't collapsing. I treat this as noise-level support, not a catalyst.
Tariff exposure is unquantified. Nike's sourcing is concentrated in Asia, but I found no tariff market or news on that region. I can't assess current tariff risk from this data.

7. Watch list and catalysts¶

FOMC (late October): Hike odds are the largest swing factor for rate-sensitive consumer names.
10-year yield: The Oct 5 high of 5.31% is the level to watch. A close above it would be a bearish signal.
Oct 31: The Iran ceasefire window (80% priced) and any oil spike above $103.
Nov 3: US midterms.
Next CPI release (mid-November): A second hot print would raise hike odds.
Peer earnings: Read-throughs from consumer and athletic-apparel peers for demand and promotional intensity.
Analyst actions on NKE: More cuts would confirm negative revisions. A stabilization or upgrade would be an early sign of a turn.

8. Summary table¶

Category	Key point	Data / evidence	Implication for NKE
Analyst sentiment	BofA turned bearish; HSBC cut PT to $34 from $40	News headlines (rationale not retrieved)	Negative estimate momentum
Fundamentals (headlines)	"Reset isn't working yet"; revenue declines deepen	GuruFocus and TheStreet headlines	The turnaround is unproven
Supply chain	Yue Yuen September footwear shipments rose	Footwear News	Mild positive read-through
Competitor / sector	Vans turnaround; Lululemon scrutiny	Headlines	Category competition intensifying; sector mixed
Rates	10-yr at 5.21% (peak 5.31%; +118 bp y/y)	FRED DGS10	Valuation headwind for a turnaround stock
Fed	Fed funds 3.75% (+12 bp in Sept); 82% odds of another hike; 97% no cuts in 2026	FRED; Polymarket	Higher-for-longer
Inflation	CPI +0.65% m/m in Sept, +0.40% in Aug; +3.46% since Nov 2025	FRED CPIAUCSL	Real-income squeeze; supports hike risk
Labor	Unemployment 4.2%	FRED UNRATE	Supports spending volumes; limits recession risk
Recession risk	US recession by end-2026: 8%	Polymarket	Low; the risk is valuation, not demand collapse
Energy / geopolitics	Oil about $103; Iran ceasefire 80% through Oct 31; 16% odds of invasion	Yahoo headline; Polymarket	Cost and consumer headwind; tail risk
Consumer credit	Mortgage rates at a near 3-year high ("Is 8% next?")	Yahoo headlines	Discretionary spending pressure
Market tone	BlackRock more bearish; bubble-valuation worries; global bond-yield surge	Yahoo headlines	Risk-off tilt; high-multiple stocks vulnerable
Positioning	"Down 80% from high"; contrarian-buy articles	Motley Fool, MarketBeat	Sentiment washed out, but "structural" counter-narrative
Key dates	FOMC late Oct; Oct 31 ceasefire window; Nov 3 midterms; mid-Nov CPI	Prediction markets; calendar	Event-heavy window
Data gaps	Core PCE, core CPI, VIX, yield curve, 2Y yield, sentiment, retail sales (FRED 403); no price data; no tariff or oil markets	Tool errors	Needs follow-up by another agent

Fundamentals Analyst¶

NKE (NIKE, Inc.) Fundamental Report¶

As of 2026-10-14. Sector: Consumer Cyclical. Industry: Footwear & Accessories. Exchange: NYQ.

Financial statement figures are from SEC EDGAR filings (USD millions unless noted). The latest period is Q1 FY27, which ended 2026-08-31. Nike's fiscal year ends May 31. Nothing in the insider data falls within the last seven days. The newest entry is a director grant on 2026-09-15.

1. Key takeaways¶

Trailing earnings look better than they are. TTM EPS is $2.08 and trailing P/E is about 17x. About a third of TTM net income comes from one quarter, Q4 FY26, which I derived at roughly $1.07B. The other three quarters in the TTM window average about $675M. Forward EPS is $1.68, which puts forward P/E near 21x. The market expects earnings to fall from the trailing figure.
The top line is still shrinking. Q1 FY27 revenue was $11.21B, down 4.3% year over year. FY26 revenue was flat at $46.4B, about 10% below the FY24 peak of $51.4B.
Free cash flow no longer covers the dividend. FY26 free cash flow was about $2.18B. The dividend costs roughly $2.4B a year, which I inferred from the 4.64% yield. Q1 FY27 operating cash flow was $135M against $199M of capex, so free cash flow was about –$64M.
The balance sheet is solid but eroding slowly. Cash is $6.9B, the current ratio is 2.08, and equity is $15.2B. Cash is down from $9.9B at the FY24 peak.
Insiders bought heavily into weakness, and none has bought since April 2026. Open-market buys since November 2025 total about $9.2B... correction: about $9.2M. Sales since June 2026 are small, about $1.6M, and look mostly vesting-related.

2. Valuation and market snapshot¶

The tool doesn't give the share price directly. Market cap divided by book value per share, and P/E times EPS, both imply a price of about $35.3.

Metric	Value	Comment
Market cap	$52.43B
P/E (TTM) / Forward P/E	16.97x / 20.99x	Forward is higher than trailing, so earnings are expected to fall
PEG	1.5
Price/Book	3.44x	Book value per share is $10.26
Price/Sales (derived)	~1.14x
EV/EBITDA (rough, derived)	~11–12x	EV ≈ $52.4B + ~$11.1B debt (from D/E) – $6.9B cash. Short-term investments and lease treatment are unknown.
Dividend yield	4.64%	About $1.64 per share a year, inferred
Beta	1.10
52-week range	$31.97 – $70.44	The price is about 10% above the low and about 50% below the high
50-day / 200-day average	$37.75 / $47.64	The price is below both, and the 50-day is well below the 200-day
ROE / ROA	21.6% / 6.9%
Margins (TTM)	Gross ~43%, operating 7.9%, net 6.7%
EBITDA / Net income (TTM)	$4.89B / $3.09B
Debt/Equity	0.73x
Current ratio	2.075	Matches my calculation from the Aug-2026 balance sheet
FCF (TTM, per fundamentals)	$1.77B	This is about 3.4% of market cap, below the 4.64% dividend yield

3. Income statement¶

Annual trend (fiscal years ending May 31)¶

FY	Revenue	Gross profit	Gross margin	Net income	Net margin	Diluted EPS
FY22	46,710	21,479	46.0%	6,046	12.9%	3.75
FY23	51,217	22,292	43.5%	5,070	9.9%	3.23
FY24	51,362	22,887	44.6%	5,700	11.1%	3.73
FY25	46,309	19,790	42.7%	3,219	7.0%	2.16
FY26	46,398	19,911	42.9%	3,108	6.7%	2.10

Revenue fell 9.8% from FY24 to FY25 and was flat in FY26.
EPS has dropped 44% from the FY24 level of $3.73.
Gross margin has stabilized near 43%, but it is still about 170 basis points below FY24. Net margin has been cut roughly in half from FY22, so operating costs are absorbing more of each sales dollar.
Operating income is not tagged in the filings. I only have the TTM operating margin of 7.9% from the fundamentals tool.

Quarterly detail¶

Q4 is not in the quarterly feed, so I derived it as the annual figure minus Q1–Q3.

Quarter	Revenue	YoY	Gross profit	GM	Net income	EPS
Q1 FY26 (Aug-25)	11,720	+1.1%	4,943	42.2%	727	0.49
Q2 FY26 (Nov-25)	12,427	+0.6%	5,045	40.6%	792	0.53
Q3 FY26 (Feb-26)	11,279	+0.1%	4,530	40.2%	520	0.35
Q4 FY26 (May-26, derived)	10,972	–1.1%	5,393	49.2%	1,069	0.73
Q1 FY27 (Aug-26)	11,213	–4.3%	4,798	42.8%	712	0.48

Q1 FY27: Revenue fell 4.3% and net income fell 2.1%. Gross margin rose about 60 basis points year over year, from 42.2% to 42.8%, and net margin edged up from 6.2% to 6.35%. Margins held up, but the revenue trend turned negative again.
Q4 FY26 is an outlier. The derived gross margin of 49.2% compares with 40–43% in every adjacent quarter, and net income of $1.07B compares with $520M the quarter before. I used the same method on FY25 and it reproduces the known Q4 FY25 figures: revenue $11,097M, net income $211M, EPS $0.14. So the method works, and the Q4 FY26 figure is what the filings imply. Verify the cause in the 10-K, such as a one-time gain, a benefit from a cost reclassification, or a tax item.
Effect on TTM: I rebuilt TTM from annual data and it ties to the fundamentals tool. Revenue is $45,891M, net income is $3,093M, and EPS is about $2.09. TTM gross profit comes out at $19.77B against the tool's $19.92B, a small mismatch I couldn't resolve. When Q4 FY26 drops out of the TTM window, trailing EPS will fall sharply unless Q4 FY27 repeats it.
Normalized run-rate: Q1–Q3 FY26 net income was $2,039M, down 32% from $3,008M in the same quarters of FY25. Q1 FY27 net income of $712M is in line with a $2.7–2.9B annualized pace. That is below the TTM $3.09B and consistent with the $1.68 forward EPS.

4. Balance sheet¶

Date	Total assets	Current assets	Cash	Current liabilities	Equity	Current ratio
May-24	38,110	25,382	9,860	10,593	14,430	2.40
May-25	36,579	23,362	7,464	10,566	13,213	2.21
Aug-25	37,334	23,898	7,024	10,911	13,468	2.19
Nov-25	37,787	24,015	6,974	11,640	14,085	2.06
Feb-26	37,064	23,184	6,660	10,838	14,090	2.14
May-26	38,410	24,603	7,563	12,547	14,865	1.96
Aug-26	37,794	23,673	6,903	11,409	15,220	2.07

Liquidity is fine but trending down. The current ratio has slid from 2.4 to about 2.1, and cash is about $3B below the FY24 level. Cash fell $660M in Q1 FY27.
Equity is rising even with the dividend. It grew from $13.2B to $15.2B over five quarters. That is consistent with buybacks having been largely paused, which I inferred from the cash flow data and did not see directly.
Gaps in this data: Total liabilities are not tagged. Implied total liabilities are about $22.6B (assets minus equity). The feed has no inventory, debt, or lease detail. D/E of 0.73x is from the fundamentals tool, and I can't tell whether it includes operating leases.

5. Cash flow¶

Annual¶

FY	Operating CF	Capex	Free cash flow	Financing CF
FY22	5,188	758	4,430	–4,836
FY23	5,841	969	4,872	–7,447
FY24	7,429	812	6,617	–5,888
FY25	3,698	430	3,268	–5,820
FY26	2,868	684	2,184	–2,292

Recent quarters (cumulative year-to-date as reported)¶

Period	Operating CF	Capex	FCF
Q1 FY26	222	207	15
9M FY26	1,231	546	685
9M FY25	3,235	330	2,905
Q1 FY27	135	199	–64

Free cash flow has fallen about 67% from FY24, from $6.6B to $2.2B.
Cash conversion is poor. FY26 operating cash flow of $2.87B is below net income of $3.11B. Nine-month FY26 operating cash flow was down 62% year over year, and capex rose.
The dividend is not covered. The implied dividend is about $2.4B a year, or about $610M a quarter. That is roughly 110% of FY26 free cash flow, and about 79% of FY26 EPS ($1.64 vs $2.10). It is about 98% of the $1.68 forward EPS. Q1 FY27 financing outflow was $618M, almost exactly one quarter's dividend, so buybacks appear minimal. Q1 free cash flow was negative, so the dividend was funded from the cash balance.
Dividend risk: The 4.64% yield is high partly because the price has fallen. If operating cash flow doesn't recover, the cash balance or debt has to fund the payout. I can't see the board's intent from these tools.

6. Insider transactions¶

Open-market purchases¶

Date	Insider	Shares	Price	Value
2025-11-07	Knudstorp (Dir.)	16,150	$62.09	$1.00M
2025-12-22	Cook (Dir.)	50,000	$58.97	$2.95M
2025-12-22	Swan (Dir.)	8,691	$57.54	$0.50M
2025-12-29	Hill (CEO)	16,388	$61.10	$1.00M
2026-04-07	Swan (Dir.)	11,781	$42.44	$0.50M
2026-04-09	Rogers (Dir.)	4,000	$43.34	$0.17M
2026-04-10	Cook (Dir.)	25,000	$42.43	$1.06M
2026-04-13	Hill (CEO)	2 × ~23,660	$42.26–42.27	$2.00M

Total: About $9.2M since November 2025, from five insiders including the CEO. Earlier buys were Swan in April 2025 (about $0.5M) and Rogers in December 2024 (about $0.19M).
They are underwater. The April 2026 buys at about $42–43 are roughly 17% below cost at an implied price near $35. The December buys at $57–61 are down about 40%.
No open-market buys since April 13, 2026. The April cluster was about $3.7M.

Sales¶

Mark Parker (Exec. Chair) sold about $41.9M from February to November 2025: five sales at $62–76, with some paired with exercises of options struck at $56.40. His Nov 2024 sale was about $3.5M. He has had no recorded sales in 2026, only gifts.
Recent officer sales total about $1.6M since June 2026:
McCartney sold $803K at $46.18 on 2026-06-12.
Montagne sold $205K at $42.05 on 2026-08-07.
Friend, Leinwand, McCartney and Alagirisamy sold $34K–$102K each at $41.60 on 2026-08-05.
Leinwand, McCartney and Alagirisamy sold $96K–$138K each at $37.59 on 2026-09-09.
These look vesting-related. The sales share an identical price on the same day and follow equity grants on Sep 1, so they are consistent with sell-to-cover. That is an inference, and the data doesn't confirm it.

Grants and gifts¶

Executive grants on 2026-09-01: CEO Hill received 108,400 shares and CFO Denton received 71,234.
Director grants: Each of nine directors got 5,047 shares on 2026-09-08. That compares with 2,619 in September 2025, about 1.9x the share count.
Large gifts (indirect or family holdings): Travis Knight gifted 2.85M shares on 2026-07-30. Philip Knight gifted 4.5M shares on 2026-02-11. Gifts are not sales, but the size is notable and the purpose is unknown.

Management change¶

The 2026-08-05 sale lists Matthew Friend as CFO. The 2026-09-01 grant lists David M. Denton as CFO. That suggests a CFO transition between those dates. Confirm it through filings or news, which my tools don't cover.

Reading the insider data¶

Directors and the CEO showed conviction near $42–62, and sales since then are small and look routine. The absence of new buying since April, with the price now about 17% lower, is worth noting. Insider buying is not a guarantee of a turnaround.

7. Data limitations¶

No price feed. The ~$35.3 price is inferred.
Fiscal Q4 is missing from the quarterly feed, so Q4 figures are derived.
Operating income and total liabilities are not tagged in the filings.
No segment, geographic, or channel data, so I can't separate Nike Direct, wholesale, China, or North America.
No inventory, debt, buyback, or guidance detail.
No analyst estimates beyond forward EPS, and no news or sentiment.
The insider table leaves the transaction-type column blank. It also has apparent duplicate rows: Parker's gifts on 2026-05-14 and Hill's two same-day purchases.
Dividend per share and dividend dollars are my inference from yield, price, and share count.

8. What to watch¶

Q2 FY27 results (next report, likely around late December, based on past timing): Watch the revenue trend (Q1 was –4.3%), whether gross margin holds near 42–43%, and whether net income stays near $700–800M.
The Q4 FY26 anomaly. Find out whether the 49% gross margin and $1.07B net income were one-time. That decides whether trailing P/E of 17x or forward P/E of 21x is the better guide.
Dividend policy. Free cash flow has been below the payout for a year. Watch for any change in dividend or buyback language.
Operating cash flow recovery. Q1 FY27 was $135M. Inventory and working capital detail would help, and it needs the 10-Q.
Insider behavior. Watch for new open-market buys near these levels and for any resumption of sales by Parker.
Leadership. Confirm the CFO change.

I'm leaving the buy/sell decision to the next agent.

9. Summary table¶

Category	Metric	Value	Signal
Valuation	Price (implied)	~$35.3	Near the 52-week low of $31.97
Valuation	P/E TTM → Forward	17.0x → 21.0x	Earnings expected to fall
Valuation	P/B / P/S	3.44x / ~1.14x
Valuation	EV/EBITDA (rough)	~11–12x	Debt and lease treatment assumed
Technical context	Price vs 50d / 200d	$37.75 / $47.64	Below both
Income	FY26 revenue	$46.4B (+0.2%)	Flat, 10% below the FY24 peak
Income	Q1 FY27 revenue	$11.21B (–4.3% YoY)	Declining again
Income	FY26 gross margin	42.9%	Stable, but below FY24's 44.6%
Income	Q1 FY27 gross margin	42.8% (+60 bp YoY)	Resilient
Income	FY26 EPS	$2.10	–44% from FY24
Income	Q1 FY27 EPS	$0.48 (vs $0.49)	Roughly flat
Income	Q4 FY26 (derived)	NI $1,069M, GM 49.2%	Outlier, flatters TTM; verify
Profitability	Net / operating margin (TTM)	6.7% / 7.9%	Compressed vs FY22's 12.9% net
Profitability	ROE	21.6%	Still healthy, helped by a shrunken equity base
Balance sheet	Cash	$6.9B	Down from $9.9B in FY24
Balance sheet	Current ratio	2.08	Fine, drifting down
Balance sheet	Equity	$15.2B	Rising
Balance sheet	D/E	0.73x	Moderate
Cash flow	FY26 FCF	~$2.18B	Down 67% from FY24
Cash flow	Q1 FY27 FCF	~–$64M	Negative
Dividend	Yield	4.64% (~$1.64/share, inferred)	Not covered by FCF
Dividend	Payout on forward EPS	~98%	Elevated risk
Insiders	Open-market buys since Nov-2025	~$9.2M (CEO, Cook, Swan, Knudstorp, Rogers)	Bullish signal, now underwater
Insiders	Most recent buy	2026-04-13	None in the last six months
Insiders	Sales since Jun-2026	~$1.6M (officers)	Likely vesting-related
Insiders	Parker sales (2025)	~$41.9M; none in 2026	Selling stopped
Insiders	Management	CFO changed (Friend → Denton)	Verify
Data gaps	Segment, inventory, debt, guidance, news	Not available	Needs other sources

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # Bull Case for NKE: A Quality Franchise Priced for Permanent Decline

Bear, I'll open, since you haven't spoken yet. I'm not going to pretend NKE is a clean story. Revenue is shrinking, the trend is down, and the macro is ugly. My argument is that at $35.30, after a ~51% drop in 12 months, these facts are already in the price, and the evidence that the business is stabilizing is being ignored.

1. The bar is low and the franchise is intact¶

Margins held while revenue fell. Gross margin was 42.9% in FY26 and 42.8% in Q1 FY27, up ~60 bp YoY (42.2% a year earlier). A broken brand discounts its way to the floor. NKE is not doing that.
Earnings are stabilizing. Q1 FY27 EPS was $0.48 vs. $0.49, and net income $712M vs. $727M. Revenue fell 4.3%, but profit is roughly flat. The cost reset is working.
ROE is 21.6%. The business still earns strong returns on capital.

I'm not claiming a V-shaped recovery. I'm claiming the stock is priced as if there will never be one.

2. Valuation is asking for very little¶

Price/sales is ~1.14x. FY24 peak revenue was $51.4B, and NKE's market cap is $52.4B. You can buy the company for roughly one year of peak sales.
Operating leverage is the thesis. This is illustrative, not a forecast. If revenue merely returns to FY24's $51.4B at today's 6.7% net margin, EPS is ~$2.30. At a 9% margin, which is still well below FY24's 11.1%, EPS is ~$3.10, so the stock trades at ~11x. FY24 EPS was $3.73, and today's price is under 10x that.
The 4.6% dividend ($0.41 per quarter, unchanged across four consecutive payments) pays you to wait.

3. The balance sheet buys time¶

$6.9B in cash, a 2.08 current ratio, and 0.73x debt/equity. Equity is rising ($13.2B to $15.2B in five quarters).
The dividend costs ~$2.4B a year, so cash alone covers more than two and a half years of it.

4. Insiders put real money in¶

Five insiders, including CEO Hill, bought ~$9.2M in the open market between November 2025 and April 2026. These were not option exercises or grants. Directors also got ~1.9x the share count in their September grants. Mark Parker's selling stopped: he sold ~$41.9M in 2025 and has had no recorded sales in 2026. Recent officer sales total ~$1.6M, are tiny, and look like sell-to-cover at identical prices.

5. The tape shows exhaustion, not fresh liquidation¶

The 10-02 capitulation gap came on 142.7M shares, the heaviest volume in the sample. It printed a 31.97 low but closed at 33.87, a ~6% recovery off the lows.
Weekly and monthly TD-9 buy setups have both completed, and weekly and monthly Z-scores are at -1.30 and -1.56.
RSI bounced from 28.49 to 43.82. The MACD histogram has been positive eight straight sessions. The 10-02 gap has been fully traded back through. ADX is fading from 36.7 to 22.4, so the downtrend is losing force.
Relative strength: even the loudest bear on StockTwits admits NKE has "hardly any red" on a red market day.

6. Sentiment is washed out¶

The week's headlines are "down 80% from its high," "reset isn't working," a BofA downgrade, and an HSBC target cut to $34. The HSBC target sits at the current price. When a bearish analyst's target equals the stock price, that is not much of a downside argument.

The StockTwits "72% bearish" figure comes from one account holding puts: 17 of 18 messages, and the effective sample is ~2 users.

Where I expect you to push, and my answers¶

"Revenue is still falling, down 4.3%." True, and it's the main risk. But gross margin rose in that same quarter and profit was flat, so the decline isn't coming from price erosion. The comp is also easy. Yue Yuen's September shipments rose and the Vans turnaround is showing green shoots, so category demand isn't collapsing.

"Free cash flow doesn't cover the dividend." Fair. FY26 FCF was $2.18B against a ~$2.4B payout, and Q1 FCF was about -$64M. That is a watch item. But it's a cash-cycle issue against a $6.9B cash pile, not a solvency issue. The dividend figures are my inference from yield, not tagged filings.

"TTM P/E of 17x is flattered by an outlier Q4." I agree, and I won't use it. Q4 FY26's derived 49% gross margin and $1.07B of net income look anomalous. So I'm using forward EPS of $1.68, a ~21x P/E on trough earnings, and the normalized run-rate of ~$2.7–2.9B in annual net income. The case rests on recovery in the denominator, not on the trailing multiple.

"10-year at 5.21%, hikes coming, oil at $103." This is a real headwind for a duration-style recovery story. But unemployment is 4.2% and Polymarket puts recession odds at 8%. The macro risk is multiple compression, and NKE has already de-rated about 51% while the 10-year rose 118 bp. If yields roll over from 5.3%, this is a high-beta beneficiary.

"Every SuperTrend tier is down and OBV isn't confirming." Agreed. That's why I'm not calling a trend change yet. But the technical report itself notes OBV overstates distribution on tiny down closes, and volume is the lowest since August, which fits sellers drying up. A close above 36.38 flips the daily tier, and the next marker is the 50 SMA at 37.59.

Risk and reward¶

Downside to the 10-02 intraday low (31.97) is ~9.4%. Upside runs +6.5% to the 50 SMA, +21.5% to the weekly SuperTrend at 42.88, and +32.8% to the 200 SMA, plus a ~4.6% yield while you wait. That asymmetry is attractive for a brand with 43% gross margins.

What would change my mind¶

Q2 FY27 revenue declines deepening and gross margin breaking below ~40%
A dividend cut, or free cash flow staying negative for another quarter or two
A close below 31.97 on volume
Evidence that the Q4 FY26 anomaly reflects something worse than a one-time item

My data has real gaps: no guidance, inventory, segment, or China detail, and the news is headline-only. So bear, what's your strongest argument that this is structural and not cyclical? Show me where margins or the balance sheet crack. Bull Analyst: # Bull Rebuttal: Answering Your Question, Then Defending What Survives

Bear, you asked for a revenue or cash-flow datapoint that is improving. Revenue isn't. Q4 FY26 was -1.1% (derived) and Q1 FY27 was -4.3%, and that is the weakest line in the file. I won't dress it up. The rest is below.

1. What is improving¶

Two-quarter free cash flow is up sharply. Q4 FY26 plus Q1 FY27 is about $1.50B - $0.06B = $1.44B. A year earlier, Q4 FY25 plus Q1 FY26 was $0.36B + $0.015B = $0.38B. These figures are derived from annual and year-to-date numbers. You're right that Q4 needs explaining. But current liabilities rose $1.7B in Q4 and gave back $1.1B in Q1, so one quarter's FCF in either direction is a poor guide. Summing the two removes some of that timing.
The earnings decline rate collapsed. Q1-Q3 FY26 net income was -32% YoY, and Q1 FY27 was -2%. You call that "flat against a lower base." That is what stabilization looks like.
Gross margin is the best of the clean quarters. Q1 FY27 was 42.8%, against 42.2%, 40.6% and 40.2% for Q1-Q3 FY26. I'm excluding Q4's 49%, as you said I should.
Working capital isn't building on a seasonally matched basis. Non-cash current assets were $16.77B in Aug-26 against $16.87B in Aug-25 (-0.6%). Your +$872M since May-25 is correct, but +$976M of it landed in the first quarter. The series has stayed in a $16.5-17.0B band for five quarters since. The line isn't inventory-tagged and may include short-term investments.

2. What I'm conceding¶

"Priced for permanent decline" was overstated. A year ago NKE traded at ~33x FY25 EPS ($72.19 / $2.16). Today it's 21x forward. The 51% drop is roughly -22% from earnings ($2.16 to $1.68) and -37% from the multiple, and the two compound. A lot of recovery premium is gone, but not all of it.
The director grants carry no signal. 5,047 shares at ~$37.59 and 2,619 shares at ~$72 both come to about $190K. That is a fixed-dollar grant, and I'm dropping the point.
Parker's silence is not conviction. It means the overhang is gone.
The tape is unconfirmed. Z-scores of -1.3 and -1.6 aren't extremes, and the weekly and monthly TD-9s are provisional. The risk/reward to the first overhead levels (36.38 to 37.59) is ~0.7:1, and your arithmetic is right.

3. Where I think you overreach¶

The cost reset. You measured costs as a share of revenue. In dollars:

Q1 FY27 vs Q1 FY26	Change
Revenue	-$507M
Gross profit	-$145M
Costs below gross profit	-$130M
Net income	-$15M

Lower costs offset ~90% of the gross profit decline, and net income fell just 3 cents per lost revenue dollar. A share-of-revenue view penalizes any fixed cost during a revenue dip. That deleverage is what reverses on the way up. The caveat is that "below gross profit" includes tax and other items, so I can't isolate opex.

The dividend and the cash story. - Rebuilding TTM FCF from filings gives OCF of $2,781M less capex of $676M, or $2.1B. The tool says $1.77B, and I can't reconcile the ~$330M gap. As a range, FCF is $1.8-2.1B against a ~$2.4B dividend, or 73-87% coverage. That is a shortfall, not a chasm. - Of the $3.0B cash decline since FY24, $2.4B came in FY25, when financing outflows were $5.8B against $3.3B of FCF. That implies buybacks. In FY26 cash rose $99M while the dividend was paid. Q1 is seasonally weak: cash fell $440M last Q1 and $660M this Q1, which is $220M worse and not a bleed. - A dividend cut is on my kill list. It is the board's lever, but I don't see it forced by this balance sheet.

Structural vs. cyclical is a false binary. No recession doesn't make this structural. Product, inventory and channel cycles are real cycles. Share loss to better product usually shows up as discounting, and here gross margin rose while revenue fell. That fits deliberate pruning or a cleanup. Without segment data I can't prove it, so I'm flagging it as a hypothesis. I'll also stop leaning on Vans and Yue Yuen, since we're both reading headlines.

Insiders. Percent of market cap is the wrong denominator, because nobody buys 1% of a $52B company. A grant is compensation, but a purchase is a decision made with after-tax cash. Hill, Cook and Swan each bought twice. Hill doubled his size from $1.0M to $2.0M after a 31% drop. You're right that nobody has bought since April 13 and that everyone is underwater. I can't verify blackout timing, so I won't lean on it. Insider buying is corroboration, not a pillar.

Sell-side. "Estimates are still falling" rests on two headlines whose rationale wasn't retrieved. A cut from $40 to $34 could reflect a lower multiple, which fits a 118 bp rise in the 10-year. HSBC's $34 is 3.7% below the price, so even the cautious end isn't calling for much more downside. I weight the sell-side low in both directions.

Treasury vs. dividend. A 5.21% Treasury beats a 4.64% yield. But a Treasury has no recovery option, and the real issue is the discount rate. I called that the biggest external risk, and the multiple has already compressed 37% as yields rose. I'm not claiming yields will fall. I'm claiming the thesis doesn't need them to.

Relative strength. A put-holder complaining that NKE isn't falling is a statement against interest, which deserves more weight than his bearish calls. It's one day of data, so I'll hold it lightly.

4. What you need to believe at $35.30¶

Shares are ~1.485B (market cap / price). I'm using your multiples:

Scenario	Revenue	Net margin	EPS	@15x	@18x
Street forward EPS	n/a	n/a	$1.68	$25	$30
Q1 run-rate holds	$44.9B	6.35%	$1.92	$29	$35
Revenue stabilizes at FY26	$46.4B	7.5%	$2.34	$35	$42
Half-recovery	$48.6B	8.5%	$2.78	$42	$50

At 18x, today's price is "Q1 run-rate forever." At your 15x, today's price is revenue merely stopping at FY26's level with a 7.5% net margin. FY25 was 7.0% and FY24 was 11.1%.
The $1.68 forward EPS is 12.5% below Q1's annualized $1.92. If revenue keeps falling 4.3% to ~$44.4B, it implies a ~5.6% net margin, 75 bp below Q1's. That would come in a quarter when gross margin was rising and dollar costs were falling. I don't have guidance, so if management guided down, the bar is realistic. If not, the bar is low.

5. How I'd express it¶

I agree the first overhead levels are checkpoints and not targets. The thesis runs over several quarters, so the sizing should reflect that: - Take a starter position now. - Add on a daily close above 36.38. - Add again if Q2 shows gross margin at or above 42% and a narrower revenue decline. - Invalidate on a close below 31.97.

The yield pays you to wait, and recovery is the upside.

6. Updated kill list¶

Q2 FY27 revenue decline deeper than -4.3% for a second straight quarter.
Gross margin back below ~41%, which would erase the Q1 gain.
Another negative-FCF quarter, or any dividend cut.
A Q4 FY26 explanation showing a one-off boost to earnings and cash, which would cut my normalized EPS and my multiple.
A close below 31.97.

My questions back¶

You say the trough is still ahead. Which line item takes net margin from 6.35% to the 5.6% that $1.68 implies, when gross margin is up and dollar costs are down? And if revenue simply stops falling near $46B, what multiple do you hold on $2.34? At 15x that's today's price, and anything above 15x is upside. Bull Analyst: # Bull Response: Retiring the Table, Keeping the Thesis

Bear, I'll answer your two questions first. We now agree on expected EPS, so what remains is the multiple, the Q4 FY26 bridge, and how to size event risk on NKE.

1. What you got right¶

Row 3 was mislabeled. Q2-Q4 revenue of $35.19B against $34.68B is +1.5% YoY, which is a turn and not a stop. A 7.5% net margin is also 175 bp above the clean 5.76%. I'm retiring the row.
Q4 FY26 can't be both my evidence and my open question. I'm withdrawing the two-quarter FCF comparison as an "improving datapoint." The only lines improving are YoY gross margin (+60 bp), the rate of earnings decline (-32% to -2%), and costs flexing in dollars. None is a revenue or cash-flow line, and I won't pretend otherwise.
Gap risk is real. A close-based stop doesn't protect against it.

2. Your question: why is the top-two probability above 50%?¶

It isn't. I'm at 30% on your top two rows (30/40/20/10, against your 30/35/25/10). That is $2.02 of expected EPS against your $2.04. We agree on earnings, which has three consequences:

Your opening mirror case was -14% to -29%. Your EV is now $33.7, or about -5% on price and roughly 0% with the dividend. That is "fairly valued," not a short.
Your scoreboard bullet is inconsistent with your own table. The "4.8% earnings yield under a 5.21% Treasury" uses $1.68, the lowest row in your table. On your probability-weighted $2.04, the yield is 5.8%, about 57 bp over the 10-year, and the P/E is 17.3x.
The remaining dispute is the multiple. On about $2.04, 16.5x gives $33.6 and 18x gives $36.7, or +8.6% total return with the dividend. That $3 swing is the whole difference, and this file can't settle it.

On my numbers, 12-month EV is roughly -1% to +8%, close to the Treasury but with wide dispersion. I won't claim an EV edge I can't show. The case for NKE is a 4.6% carry while the evidence arrives, a quality franchise at near-trough earnings, and a position sized for the uncertainty.

3. Where your numbers lean the wrong way¶

The "33% coverage" figure is asymmetric. It deletes Q4 FY26, when current liabilities rose $1.7B, but keeps Q1 FY27's -$64M, which absorbed the $1.1B give-back. Pair the quarters, or use the full year:

Window	FCF	Dividend (~$610M/qtr, inferred)	Coverage
Your "ex-Q4" (Q2, Q3 FY26 + Q1 FY27)	$606M	$1,830M	33%
Q4 FY26 + Q1 FY27 (paired)	$1,435M	$1,220M	118%
TTM (all four quarters)	$2,105M	$2,440M	86%
TTM less the whole YoY rise in current liabilities (+$498M, a rough proxy)	~$1,607M	$2,440M	66%

The tool's $1.77B sits inside that range. The dividend is under-covered on every reading, but the range is 66-86%, not a third. Capex also rose from $430M in FY25 to $676M TTM. That is a lever, not a forecast.

Your gross-margin "slide" scenarios are the YoY gain restated. Repeating last year's Q1-to-Q2 slide gives 41.2%, and Q1-to-Q3 gives 40.8%. Against the year-ago 40.6% and 40.2%, both are +60 bp YoY, exactly Q1's gain. The seasonal slide is already in last year's base, so the right kill line is a YoY decline (Q2 below 40.6%), not an absolute 41%. I'm restating it that way. Caveat: this is one year of seasonality, and FY26's Q2-Q3 slide may have had a one-off driver.

"The trough is still ahead" is a Q4 call. I assume revenue falls 4.3% every remaining quarter and Q2-Q3 net margins sit at last year's levels plus Q1's +15 bp. Q1-Q3 net income is then about $2.0B, and EPS depends on Q4:

Q4 FY27 net income	Basis	FY27 EPS
$211M	repeat Q4 FY25	$1.49
~$493M	what the Street's $1.68 requires (4.7% margin)	$1.68
$640M	average of the two Q4s on file	$1.78
$1,069M	repeat Q4 FY26	$2.07

The Street's number embeds a Q4 below the two-year average. It's also a ±$0.29 bet on a quarter neither of us can explain, so "trough ahead" and "trough behind" are the same unverified call.

4. Your question: why own it into the print instead of after?¶

The Q4 explanation isn't a December event. The FY26 annual figures in our file come from EDGAR, so the 10-K and the Q4 release already exist. You said you'd want to read the bridge before sizing anything. I agree, and that is the gating item, not the Q2 print. If it shows a one-time gain, I cut my multiple and my starter goes to zero. If it shows a durable change, your normalized EPS is too low. Either way it resolves before the print.

"Waiting costs 1.2%" holds only if the expected gap is zero. The $0.41 goes ex around 12/01, before the print. Your case for waiting needs the expected gap to be worse than -1.2%. - For you: three of three prior gaps were down, and earnings surprises are autocorrelated. That is your best argument, and it's why I want a third of a position. - Against you: $1.68 is already 12.5% below Q1's annualized $1.92. You've also discounted the sell-side evidence yourself, since HSBC's $34 isn't a downside call and "estimates still falling" rests on two headlines.

Sizing is the stop, not the chart. A third of target size turns a -15% gap (the April move) into -5% of target, and a gap to 31.97 into about -3%. I'm treating 31.97 as a thesis check, not a loss limit.

Your re-entry criteria are late by construction. A weekly close above 37.59 is at least 6.5% higher, and positive YoY revenue is several quarters away. That's the price of certainty, and it's fine to pay it, but it's more than 1.2%.

5. Revised plan and kill list¶

Read the Q4 FY26 bridge first. If it's a pure one-off, no position.
Starter: one-third of target.
Second third: after Q2, if gross margin is at least 41.2% (+60 bp YoY holds) and the revenue decline is narrower than -4.3%.
Final third: your trigger, a weekly close above 37.59 with RSI above 50.

Kill list: - Q2 revenue decline deeper than -4.3%. - Q2 gross margin below 40.6% (a YoY decline). - Two consecutive negative-FCF quarters, or any dividend cut. - A Q4 bridge showing a one-off. - A close below 31.97, as a thesis check.

6. My questions back¶

What is your evidence that the expected gap is worse than -1.2%? You've already discounted the sell-side evidence.
If the bridge shows Q4 FY26 was durable, would you pay 17-18x on $2.04 or more at $35.30? If yes, we disagree about one document that both of us can read.

We agree on EPS and on the dividend's under-coverage. We also agree the Q4 bridge is the gating item. The open question is whether a third of a position in NKE is worth the gap variance in exchange for a 4.6% yield while the evidence comes in. I say yes, and you say wait. Both are defensible, but mine gets paid while we wait. Bull Analyst: # Bull Closing: One Document, One-Third of a Position

Bear, you landed most of your hits this round. I'll say which ones, then say where your framework still tilts.

1. What I'm conceding¶

$2.04 is not FY27 EPS. Your arithmetic holds. With Q1-Q3 FY27 near $2.0B, $2.04 needs a Q4 near $1.0B. My four rows were run-rate scenarios, and I let "we agree on $2.04" claim more than it did. Clean FY27 is about $1.75-1.80, or ~20x at $35.30.
Your 53%/72% break-even math is correct for your two states.
No one should treat 49% gross margin as a run-rate. Q1 FY27 at 42.8% settles that.
I can't show a 12-month EV edge. On your multiples and a 55-60% chance that Q4 was a one-off, my EV is around zero to slightly negative. On mine it's modestly positive. Neither beats a 5.2% Treasury by an equity premium, so that isn't my case.

2. Where your framework still tilts¶

a) Your Q4 test rejects a hypothesis nobody holds. "Q1 FY27 gave back 640 bp" disproves "Q4 was a new run-rate." It doesn't test "Q4 was the year-end settling of the first three quarters." The two Q4s on file are mirror images:

	9M margin	Q4 margin	Full year
FY25	8.5%	1.9%	7.0%
FY26	5.8%	9.7%	6.7%

The nine-month margin moved 2.8 points between years. The annual margin moved 0.3. Annual gross margin reads 42.7%, 42.9%, then 42.8% in Q1 FY27. The steady series in the file is the annual one.

Annual-margin reading: Q1's 6.35% on $44.4B gives $1.90, and FY26's 6.7% gives $2.00.
Consensus: $1.68 needs 5.6%, about 110 bp below the reported FY26 margin.
Your clean-quarter reading gives $1.75-1.80. That's valid only if Q4 FY26 is the distortion and not Q1-Q3.

I can't pick between them from this file, and neither can you. The bridge can.

b) Your multiple rule isn't binding. You priced 15x at a 150 bp premium to the 10-year, but your "durable" branch pays up to 20x. That's a 5.0% earnings yield, below the 5.21% Treasury. So the constraint is growth expectations, not earnings yield. The dispute is whether revenue stops falling, which Q2 and the bridge speak to directly.

c) Your "one-off" range pairs corners. Its low end uses $1.68, which you now call light, at your lowest multiple. By your own math the Street is 4-7% low. Estimates that are still being cut (HSBC, BofA, headline-level only) while clean math sits above them is at least a contrarian setup, though I can't verify revision data.

3. The gap evidence¶

I accept your inference that the 10-02 gap followed the Q1 print. The market may have read guidance that neither of us can see. That is the best reason to wait, and it's why I'm only asking for a third.

Two cautions: - "Three for three" describes a 51% decline. It's n=3 in a series defined by the drop, so it doesn't forecast the fourth. - If 10-02 was the Q1 print, the next scheduled company event is about ten weeks away. I don't have to decide to hold through it now. I can cut ahead of it if the tape and the bridge haven't confirmed.

You're right that sizing doesn't create edge. It makes the downside survivable while the evidence arrives.

4. What the starter is buying¶

It buys a slice of the recovery tail, not a 12-month mispricing. At my earlier half-recovery row (about +9% revenue from FY27 and ~+2 pts of net margin), EPS is $2.78. At your own 15-16.5x that's $42-46 against $35.30. It's a multi-year outcome with a modest probability, and you'd say it's under 10%. A 4.6% yield pays while the evidence arrives.

5. Final plan¶

Read the Q4 FY26 bridge. If it shows a one-time gain, I hold no position. We agree on that.
Starter, one-third of target, only after the bridge. I'll adopt one of your triggers: defer if the 10-year closes above 5.31% (the Oct 5 high) before the late-October FOMC resolves.
Second third after Q2, if gross margin is at least 41.2%, the revenue decline is narrower than -4.3%, and FCF is positive without a Q4-style swing.
Final third on a weekly close above 37.59 with RSI above 50.

Kill list: - Q2 gross margin below 40.6%. - A deeper revenue decline. - A second negative-FCF quarter or any change in dividend language. - A bridge showing a one-off. - A close below 31.97 as a thesis check.

Bottom line¶

We agree on the bridge, the dividend's under-coverage, the lack of a solvency problem, and the lack of a short. Your buy list is my add list. The only open item is whether a third of a position on a defined-risk plan, taken after the bridge is read, is worth owning before Q2.

Your wait is defensible, and I won't call it wrong. But your tree prices the franchise at fair value in the good state and gives the recovery no weight in the bad one. I'd rather own a small piece of the tail, with a dividend and a stop-by-sizing, than buy it after the evidence has already moved the price. Bull Analyst: # Bull Closing: Same Facts, a Better Entry Price

Bear, your closing was fair. I'll concede what you earned, correct three things that tilt your EV, and then fix the part of my plan you hit hardest.

1. What I'm conceding¶

The annual-margin reading isn't independent. My $2.00 uses FY26's 6.7% margin, which includes Q4 FY26, and my $1.90 applies one quarter's margin to a full year. The file can't separate the "true-up" reading from the "one-off" reading. Only the bridge can.
Reading the bridge isn't an edge. The 10-K has been public for months. Consensus at $1.68 is also mild evidence for the one-off branch, because analysts who have read it still sit below clean-margin math. I hold 55-60% on one-off, near your 55%.
The risk/reward at $35.30 is poor. It is -9.4% against +3.1% to +6.5%, or roughly 0.3-0.7:1. I'm changing the plan below.
I can't show a clear premium for a beta-1.1 equity. Sizing doesn't create edge.

2. Three corrections to your EV¶

a) The 5.21% is the 10-year, not a bill. You priced ten weeks of cash carry at "T-bills at 5.21%." In our file, 5.21% is DGS10, and the effective fed funds rate is 3.75%. The bill yield isn't in the file, but it should sit near 3.75-4.25%, not at the 10-year. - Ten weeks of cash is about 0.7%, against 1.16% for the $0.41 dividend. The gap is about 45 bp, not 16 bp. - A 12-month hurdle is a bill, not a ten-year note whose own price fell as yields rose 118 bp. The 10-year is the right comparator for the discount rate, and I've accepted that. It isn't the right comparator for a 12-month return. - This isn't edge, and I'm not claiming it is. It narrows your "EV near zero vs. 5.2%" gap by about 1.2 points.

b) Your negative branch is a multiple call. Your one-off branch earns $1.75-1.80, which is 4-7% above the Street, so the -12% comes from compressing 20x to 15-18x. You justified 15-18x with the earnings-yield rule, then conceded last round that the rule isn't binding. What replaces it is a growth judgment.

One-off branch multiple	Price range (with $1.64 dividend)	Midpoint return
15-18x (yours)	$26-32	~-12%
17-20x (near today's 20x)	$31-38	~-2%

Rerunning your tree with 17-20x in the one-off branch and everything else unchanged (35% durable at +7%, 10% tail at +29%) gives EV ≈ +4%. Your multiples give about -1% to +0.5%. Against a ~4% bill, that range straddles the hurdle, so it shows no demonstrable edge, but it also shows no demonstrable negative edge. The whole difference is one multiple assumption, and the file can't settle it.

c) "Three-for-three gaps" is weaker than it looks. The tool lists three gap-downs: Dec 18-19, Mar 31-Apr 1, and Oct 1-2. Those fit your quarterly cadence. But a fourth print would have landed in late June, and the tool flags no gap there. The stock held its 40-46 range, though it slid from $46.18 on 6/12 to $40.32 on 6/26, so I can't call that print benign. Print dates aren't in the file, so this is all inference. Still, the one print that carried the Q4 FY26 numbers apparently didn't gap down, and "every print gaps down" is at best three of four. I treat gap risk as real, but it isn't a regular event I can price.

3. The fix: price discipline, not abstention¶

Your 0.7:1 critique is a critique of buying at the midline, so I'm moving the entry.

Entry	Downside to 31.97	Upside to 36.38 / 37.59	Ratio
$35.30 (market)	-9.4%	+3.1% / +6.5%	~0.3-0.7:1
$34.00 (limit)	-6.0%	+7.0% / +10.6%	~1.2-1.8:1

The $33.8-34.2 zone is the lower Bollinger band (33.82) and the 10-02 closing low (33.87). That is a level the tape has already defended once.
If the stock never trades there, I don't own it and I lose nothing.
A fill during a gap would be at the gap price. That is why the starter is one-third of target size and 31.97 is a thesis check.

On your calendar point, the FOMC, midterms and CPI don't test the thesis, but they are the events that would hand me that entry price. Whether to hold a filled starter through the late-December print is a separate decision. I'll make it in early December on the bridge and the tape, and I'll trim if neither has confirmed.

4. Final plan¶

Read the Q4 FY26 bridge first. If it shows a one-time gain, I hold no position.
Starter, one-third of target, on limit bids around $33.8-34.2 only. Defer if the 10-year closes above 5.31% before the FOMC resolves.
Second third after Q2, if gross margin is at least 41.2%, the revenue decline is narrower than -4.3%, and FCF is positive without a Q4-style swing.
Final third on your trigger, a weekly close above 37.59 with RSI above 50.

Kill list: - Q2 gross margin below 40.6%. - A deeper revenue decline than -4.3%. - A second negative-FCF quarter or any change in dividend language. - A bridge showing a one-off. - A close below 31.97, as a thesis check.

5. What survives of the bull case¶

No solvency problem: $6.9B cash, a 2.07 current ratio, and 0.73x D/E. We agree on this.
Cost flex in dollars: Q1 total costs fell 4.5% on revenue down 4.3%. Gross margin rose 60 bp, and the earnings decline went from -32% to -2%.
Valuation hinges on one document. At $34, the true-up reading ($1.90-2.04) is about 17-18x, the bottom of your own durable range. The clean reading is about 19x, which is not cheap. I accept your "never cheap" for the one-off branch only.
The tail is small but real: a half-recovery at $42-46, with an unverified 4.6% yield as the cost of waiting.

Bottom line¶

We agree on the gating item, on the dividend's under-coverage, on the absence of a solvency problem, and that this isn't a short. The remaining dispute is narrow: you say no new money before Q2, and I say a one-third starter after a clean bridge, bought at a defined price. Neither is wrong. The EV straddles the hurdle either way, so the choice rests on whether you'd rather pay up for evidence or get a better price.

My question back: if the bridge shows a true-up and the stock is at $34, do you buy? If you do, we disagree only on price and not on the thesis, and the limit bid already handles that.

Bear Researcher¶

Bear Analyst: # Bear Case for NKE: Down 51% Is Not the Same as Cheap

Bull, you asked where margins or the balance sheet crack. I'll answer that, but first I want to challenge your title. "Priced for permanent decline" is the weakest claim in your case.

1. NKE is priced for a recovery, not for decline¶

Forward P/E is 21x on $1.68, with revenue shrinking. EV/EBITDA is ~11-12x, P/B is 3.44x, and PEG is 1.5. A stock priced for permanent decline trades at 8-10x, not 21x.
"Pays you to wait" fails against the 10-year. The dividend yield is 4.64% and the forward earnings yield is 4.8%. The 10-year Treasury is 5.21%. The Treasury pays more, with no revenue risk and no coverage problem.
Your upside math is one-sided. It needs revenue +12% above TTM ($45.9B to $51.4B) and net margin up 230 bp, from 6.7% to 9%. The margin trend has gone the other way: 12.9% to 9.9% to 11.1% to 7.0% to 6.7%. Here is the mirror case. $1.68 at 15x is ~$25 (-29%), and at 18x it is ~$30 (-14%). Both are plausible with the 10-year above 5% and 82% odds of another hike.
"Under 10x peak EPS" is anchoring. Every broken franchise looks cheap against its peak. P/S against peak revenue has the same flaw, because net margin has roughly halved. And -51% describes where the price has been, not what it is worth.

2. "Stabilizing" doesn't match the data¶

Revenue growth has decelerated five straight quarters: +1.1%, +0.6%, +0.1%, -1.1%, -4.3%. A trough doesn't look like that.
Flat EPS is flat against a lower base. Q1-Q3 FY26 net income was already down 32% year over year ($2.04B vs. $3.01B).
You dropped the Q4 FY26 outlier for P/E but kept it for margin and ROE. FY26 gross margin of 42.9% includes Q4's derived 49.2%. Excluding it, Q1-Q3 FY26 gross margin is ~41.0%, and it slid from 42.2% to 40.2% across those quarters. One +60 bp print in Q1 FY27 doesn't change that. The 21.6% ROE has the same Q4 in its numerator.
The "cost reset" is not doing the work you claim. Costs below gross profit (opex, tax and other) fell 3.1% against revenue down 4.3%, so they rose ~47 bp as a share of revenue. Gross margin gained 61 bp but net margin gained only ~15 bp, so about three-quarters of the gain never reached the bottom line. I can't isolate opex because it isn't tagged.
The $1.68 forward EPS implies ~$0.42 a quarter, below Q1's $0.48. The street expects earnings to fall further, so the trough is still ahead.

3. Cash flow cracks first, and the dividend shows it¶

Earnings quality is weak. Q1 operating cash flow was $135M against $222M a year ago (-39%) while net income fell only 2%. FCF went from +$15M to -$64M.
FY26 only looked nearly covered because of Q4. Nine-month FY26 FCF was $685M, against roughly $1.8B of dividends over those nine months (inferred). The derived Q4 FCF was ~$1.5B, about 69% of the year. That is the same quarter with the anomalous 49% gross margin. Without it the dividend is uncovered by over $1B. TTM FCF is $1.77B against a ~$2.4B payout, and the payout is ~98% of forward EPS.
"Cash covers 2.9 years" counts every dollar as distributable. Current liabilities are $11.4B, and cash is down $3B from FY24. It fell $660M in Q1 alone, roughly FCF of -$64M plus one quarterly dividend.
Possible working-capital build. Current assets other than cash rose ~$872M (+5.5%) since May 2025, while TTM revenue is flat to down. There's no inventory line, so this isn't proof. But your "no inventory data" caveat is a reason for caution, not comfort.

I'll concede this much: it's not a solvency story. D/E is 0.73x and the current ratio is 2.07. The risk is that the dividend becomes the board's pressure valve, and a dividend cut is on your own kill list. FCF has already been negative for a quarter.

4. Structural vs. cyclical¶

If this were cyclical, I'd expect an economic downturn behind it. Instead:

Unemployment fell from 4.5% to 4.2%, and recession odds are 8%. You cite those as bullish, but they make the case against you. Revenue is shrinking in a healthy labor market.
Your own evidence points the same way. Yue Yuen's shipments rose and Vans is showing green shoots. Yue Yuen's volume isn't verified as Nike's, and Vans is a direct competitor, so its recovery means more competition for shelf space. If the category is fine and NKE's revenue is -4.3%, the problem is NKE-specific, either share loss or a pullback in distribution.
Margins tell the same story. Net margin has dropped ~620 bp since FY22. About half of that is gross margin, and the rest is cost deleverage that hasn't reversed.

5. The insider signal is thinner than you suggest¶

$9.2M is 0.018% of market cap. The CEO's two purchases total ~$3.0M, at $61.10 and ~$42.27, and are down ~42% and ~16%. His Sept 1 grant of 108,400 shares is worth ~$3.8M at today's price, more than both purchases combined (grant terms unknown).
Nobody has bought since April 13. The price has fallen from ~$42 to $35 and printed $31.97 in that time. The insiders who bought at $42 and $61 didn't add at $32-35.
The director grants are mechanical. 5,047 shares against 2,619 is ~1.9x. The stock roughly halved over that window, so that is what a fixed-dollar grant produces. It is not conviction.
Parker's selling stopped after he sold $41.9M at $62-76. He cashed out near the top, so "he stopped" isn't bullish. Also, the $803K McCartney sale on 6/12 doesn't fit your sell-to-cover story, and the CFO changed between Aug 5 and Sep 1. Both are unverified and worth understanding.

6. The tape: escalating selling, not exhaustion¶

Each gap has been bigger. Gap-down volume was 108.7M (Dec), then 114.2M (Apr), then 142.7M (Oct), at -10.5%, -15.5% and -7.4%. Each was followed by a lower price. I can't tie them to catalysts from this data, but they fit a quarterly cadence, and Q2 results are due around late December.
The bounce is unconfirmed. OBV is flat since 10-05 while price rose ~3.9%. RSI is 43.82 and hasn't closed above 44.2 in 30 days. The MACD line is below zero and its histogram increments are shrinking. An almost identical positive stretch (9/24-10/1) ended in the 10-02 gap. The weekly and monthly TD-9s are provisional, because both bars are still open.
Z-scores of -1.30 and -1.56 aren't extremes. Nothing hits |2|, and the daily Z of -0.06 means the oversold condition has already worked off.
Your risk/reward is not asymmetric. The nearest levels are 36.38, 36.87 and 37.59, only +3% to +6.5% away. Against that, 31.97 is -9.4%, which is ~0.7:1. The asymmetry only appears if you use the 200 SMA at +32.8%, and that needs the trend change you say hasn't happened. The tool also warns that gaps can blow through ATR stops.
You used the loudest bear for relative strength after dismissing his 72% bearish read as ~2 users. You can't use that account only when it helps you.

7. Sentiment and macro aren't washed out¶

Sell-side is still cutting. BofA downgraded after the stock fell 51%, and HSBC cut to $34 from $40. Estimates are still falling, and analysts are trimming numbers, not just targets.
Motley Fool is already running "contrarian buy" pieces. That is early dip-buying, not capitulation.
Your yield-roll scenario is against the market. Polymarket has 97% odds of no cuts in 2026 and 82% odds of another hike. September CPI was +0.65% m/m, oil is ~$103, and mortgage rates are near three-year highs. The window includes the late-October FOMC, the Nov 3 midterms, mid-November CPI, and Q2 earnings.

Bottom line¶

NKE has shrinking revenue, a payout above forward EPS, FCF that doesn't cover the dividend, and a 21x forward multiple. The stock is also in a downtrend on every higher timeframe. The balance sheet gives it time, but time isn't a catalyst.

What would change my mind: - Revenue growth that stops decelerating, with positive year-over-year growth. - Positive FCF that covers the dividend without a Q4-style one-off. - Evidence that gross margin gains reach operating margin. - A weekly close above 37.59 with RSI above 50 and OBV confirming. - Fresh insider buying below $35.

Bull, can you point to one cash-flow or revenue datapoint from the last two quarters that is improving? Margin held in one quarter, but everything else you've cited is trading action and sentiment. Bear Analyst: # Bear Rebuttal: Both of Your Questions Have Answers

Bull, you asked fair questions and I'll answer them directly. First, what you've earned.

1. What I'm conceding¶

Your dollar table is right. The all-in version is that total costs (COGS plus everything below it) fell 4.5% on revenue down 4.3%. Net margin rose 15 bp. That is a business holding its margin through a revenue decline, and I credit it. It isn't operating leverage yet.
Working capital isn't building. Seasonally matched, non-cash current assets are $16.77B against $16.87B. I withdraw that claim. They also aren't releasing cash, but that is a weaker point.
TTM FCF is $2.1B on the filings. I get the same arithmetic: OCF of $2,781M less capex of $676M. The range is fair.
The put-holder's "hardly any red" is a statement against interest. It is one session, so I'll hold it lightly. It also came on the lowest volume since 8/24.
I weight the sell-side low. HSBC's $34 is not a downside call.

None of this is a solvency story. The question is what you're paying for.

2. Your question: which line takes net margin from 6.35% to 5.6%?¶

None has to break. Look at what NKE earned in FY26's three unremarkable quarters:

	Gross margin	Costs below GP (% rev)	Net margin
Q1 FY26	42.2%	36.0%	6.2%
Q2 FY26	40.6%	34.2%	6.4%
Q3 FY26	40.2%	35.5%	4.6%
Q1-Q3 FY26	41.0%	35.2%	5.76%
Q1 FY27	42.8%	36.4%	6.35%

$1.68 is 15 bp below last year's clean-quarter margin. At 5.6% on $44.4B, it asks for no new deterioration.
The line that moved was gross margin. It fell about 200 bp from Q1 to Q3 while the cost ratio helped. Annualizing Q1 assumes Q1 is typical, and last year it was the best of the three.
Your 41% gross margin kill line is close. Repeating last year's Q1-to-Q2 slide (-160 bp) gives 41.2%. Repeating Q1-to-Q3 gives 40.8%. I have only one year of pattern, so I can't say whether it's seasonal or a trend. Either way, Q1 is not a floor.
The $1.68 versus $1.92 gap is mostly Q4. The file has two Q4s, $211M (FY25) and $1,069M (FY26). Neither is a template, and the Q4 FY26 explanation should be in the 10-K. Neither of our toolkits pulled it, so the biggest swing factor in both our models is unexplained.

3. Your question: what multiple on $2.34?¶

The row is mislabeled. "Revenue stabilizes at $46.4B" requires Q2-Q4 revenue of $35.19B against $34.68B last year, or +1.5% YoY after -4.3% in Q1. That is a turn, not a stop. A 7.5% net margin is also 175 bp above FY26's clean 5.76% and 115 bp above Q1.

On the multiple, I'd pay 15-16x. Here is the test against the 5.21% 10-year:

P/E	Earnings yield	vs. 10-yr
15x	6.7%	+150 bp
18x	5.6%	+35 bp
21x (today, on $1.68)	4.8%	-45 bp

A beta-1.1 discretionary name whose revenue has merely stopped falling, with 82% odds of another hike, shouldn't pay 35 bp over T-bills. At 15-16x, $2.34 is $35-37. Your table shows today's price is the stabilization-plus-margin-recovery scenario at a fair multiple. That is the recovery already paid for, not a margin of safety. Upside requires 18x or more, meaning earnings recovery and multiple expansion at once, with yields at 5.2%.

Expected value, on my weights. I put 30/35/25/10 on your four rows, at a 16.5x midpoint:

Prices are $27.7, $31.7, $38.6 and $45.9.
EV is about $33.7. Add the $1.64 dividend and total return is roughly 0%, against 5.2% on the Treasury.
To beat the Treasury you need about even odds on the top two rows. I'm at 35%.

Where are you?

4. Your "improving datapoint" rests on the quarter on your own kill list¶

The $1.44B versus $0.38B comparison is arithmetically right, but:

$1,499M of the $1.44B is Q4 FY26, the quarter with 49.2% derived gross margin and $1.07B of net income. Your kill list says to cut your multiple if that turns out to be a one-off. It can't be both the proof of improvement and the item to be explained.
71% of TTM FCF came from that one quarter. The other three total about $606M (Q2+Q3 of $670M, less $64M), against roughly $1.83B of dividends. That is ~33% coverage.
Summing two quarters doesn't fully remove timing. Current liabilities at Aug-26 are still $571M above Feb-26. I can't see the year-ago window.
TTM FCF is still down ~68% from FY24's $6.6B.

On the balance sheet, you're right that the FY25 cash drawdown was buybacks, which were a choice. But FY26 financing outflow was $2.3B, basically the dividend and nothing else. The buyback shock absorber is already gone. Rising equity is the same fact, since nothing is being repurchased. The dividend is now the only discretionary outflow left, and Q1 cash fell 50% more than last Q1 ($660M versus $440M) with flat EPS.

5. Your plan: right sequence, wrong first step¶

Your adds are nearly my own criteria: a daily close above 36.38, then Q2 gross margin at or above 42% with a narrower decline. Our disagreement is the starter position.

The gaps are the problem. NKE gapped -10.5%, -15.5% and -7.4% in ten months, each on heavier volume. I can't tie them to catalysts, but they fit a quarterly cadence, and Q2 is due around late December. The last gap opened at 32.55 and bottomed at 31.97, only 58 cents from your invalidation level. A close-based stop doesn't protect against a gap.
The payoff is thin. You already agreed to +3% to +6.5% against -9.4%, about 0.7:1.
Waiting is cheap. It costs one $0.41 dividend (ex-date inferred as ~12/01), or 1.2%. Not waiting exposes you to an event type that has produced 7-15% gaps.
The first trigger is the weakest signal. A daily SuperTrend flip with ADX at 22 and flat OBV is whipsaw-prone. The last positive-MACD stretch (9/24-10/1) ended in the 10-02 gap. I'd want a weekly close above 37.59 and RSI above 50.

If Q2 shows gross margin at or above 42% and a narrower revenue decline, I'll pay up and say so.

6. Where we stand¶

What's left of your case: - One YoY gross-margin print. - Costs that flex with sales. - A cash-flow improvement that depends on an unexplained quarter. - Insider buys that are all underwater.

What's left of mine: - Five quarters of revenue deceleration. - A clean-quarter net margin of 5.8%. - About one-third dividend coverage excluding Q4. - A 4.8% earnings yield under a 5.21% Treasury. - Gap risk into a late-December print.

Where I could be wrong: if the Q4 FY26 anomaly reflects a durable change, such as a real cost-structure shift, my normalized EPS is too low and FCF is better than I'm saying. That is the one data point that could break my case, and I'd want to read the 10-K bridge before sizing anything.

My questions back: 1. What probability do you put on the top two rows of your own table, and why is it above 50%? 2. If the Q4 explanation could cut your multiple, why own the stock into the print instead of after it, when waiting costs 1.2%? Bear Analyst: # Bear Closing Rebuttal: Fair Value in the Good Case, a Large Drop in the Bad One

Bull, you retired several of your own arguments last round, and I'll retire some of mine. Then I'll answer your two questions, because the answers change the picture.

1. What I'm withdrawing¶

The earnings-yield bullet. I used $1.68 there and $2.04 in the EV table. That was inconsistent.
"33% coverage." Dropping Q4 FY26 while keeping Q1 FY27 was selective. Your 66-86% TTM range is the fair one. The dividend is still under-covered on every reading, and about $1.5B of the $2.1B TTM FCF still comes from the quarter neither of us can explain.
An absolute 41% gross-margin line. A YoY test is right, since last year's seasonal slide is already in the base.
Any claim to have an estimate of the expected gap. I don't (see section 4).

2. "We agree on $2.04" is the weakest agreement we have¶

Your own Q4 table shows why. Your assumptions put Q1-Q3 FY27 net income at about $2.0B. At ~1.485B shares, $2.04 is about $3.03B, so it needs a Q4 FY27 net income near $1.0B. That is Q4 FY26 repeating, the quarter that triggers your own kill list. The caveat is that your rows were run-rate scenarios, not FY27 forecasts. Mapped onto FY27 with your table, though, that is what they require.

What clean margins give: - Q4 FY27 revenue is ~$10.5B. At 5.8% (the clean Q1-Q3 FY26 margin) to 6.35% (Q1 FY27), net income is $0.61-0.67B. - That puts FY27 EPS at ~$1.75-1.80, 4-7% above the Street's $1.68. I concede the Street is a touch light, but not by $0.30. - At $35.30 that is 19.6-20.2x. At 15-18x it is $26-32.

On "the Street's Q4 is below the two-year average": averaging $211M and $1,069M gives a number neither quarter resembles. The Street's implied ~$493M is a 4.7% margin, inside the clean range of 4.6-6.4%, and 2.3x the only other Q4 on file.

3. Q1 FY27 already tested "durable"¶

	Revenue	Gross margin	Net margin
Q4 FY26 (derived)	$10,972M	49.2%	9.7%
Q1 FY27	$11,213M (+2.2% q/q)	42.8%	6.35%

A durable cost-structure change doesn't give back 640 bp of gross margin the next quarter on higher sales. I can't rule out a seasonal or accounting-basis effect, since derived Q4 is the annual figure minus nine months and any basis change lands in that plug. That is what the 10-K bridge is for. But the only data point after Q4 leans toward a one-off, which is on your kill list.

4. Your two questions¶

"Would you pay 17-18x on $2.04 if the bridge shows Q4 was durable?" Yes. That is $34.7-36.7, which is today's price. I'll even give you a re-rating to 20x on $2.07 ($41). All figures below are illustrative and include the $1.64 dividend.

Bridge outcome	EPS	Multiple	Price	vs. $35.30	With dividend
One-off	$1.68-1.80	15-18x	$25-32	-29% to -8%	-24% to -4%
Durable	$2.04-2.07	17-20x	$34.7-41.4	-2% to +17%	+3% to +22%

Using the midpoints (about -14% and +12%), you need roughly 53% confidence in "durable" to break even and ~72% to match the 10-year at 5.21%. Section 3 says my confidence is below that, and the Street's $1.68 says the market's is too. The bridge resolves into "fairly priced" or "broken," never "cheap." If it shows a durable change, I move to neutral and buy on Q2 confirmation.

"What's your evidence the expected gap is worse than -1.2%?" I can't give a statistical estimate. I have three points:

The gaps fit the reporting cadence. I said earlier I couldn't tie them to catalysts, but Q1 FY27 (ended 8/31) is in the filings, and the 10/01-10/02 heavy-volume window fits a report roughly four weeks after quarter-end. That is inference, not tagged data, and I can't see guidance. If it holds, the market saw the flat EPS and +60 bp gross margin you call stabilization and still gapped down 7.4% on the heaviest volume in the sample. Whatever it was looking for, it wasn't found there.
The burden runs the other way. You say you won't claim an EV edge, and your range of -1% to +8% total return sits around the Treasury's 5.2%, which is risk-free. A beta-1.1 equity should clear that by an equity premium. The carry is already inside your EV, so it isn't extra compensation for event risk.
Sizing doesn't create edge. A third of target size cuts the loss from a -15% gap to -5% of target, but it also cuts the gain by two-thirds. Sizing makes a zero-edge bet smaller. It doesn't make it a good one.

5. Where we stand¶

Agreed: - Step 0 is reading the Q4 FY26 bridge, and no position makes sense before it. - The dividend is under-covered, though not catastrophically. - It isn't a solvency story. - The stock isn't a short on these numbers. A $6.9B cash pile, washed-out sentiment and a 4.6% yield make that a bad bet.

Still disputed: only the first third. You'd hold it through a late-December print with a record of three gap-downs in three prints. After the bridge, I'd wait for Q2.

Why I'd wait: - Clean-margin EPS of $1.75-1.80 puts the stock at ~20x, not at a discount. - Your $2.04 needs Q4 to repeat, and Q1 FY27 points the other way. - Five quarters of revenue deceleration haven't turned. - A 10-year at 5.21% with hike odds at 82% pressures the multiple, and the late-October FOMC comes first. - Your expected return is at or below the Treasury, with equity-sized dispersion.

What would make me a buyer: - A bridge showing Q4 FY26 was durable. - Q2 revenue decline narrower than -4.3%, with gross margin at or above 41.2%. - Positive FCF without a Q4-style swing. - A weekly close above 37.59 with RSI above 50.

What would make me more bearish: - Q2 gross margin below 40.6%. - A second negative-FCF quarter, or any change in dividend language. - A 10-year close above 5.31%.

NKE is a good franchise at a fair price on its best-case numbers and an expensive one on its clean ones. That is not enough margin of safety to own into the next print. Bear Analyst: # Bear Final Word: Shared Facts, No Shared Edge

Bull, you've given up the $2.04 claim, the 49% margin as a run-rate, and any 12-month EV edge. I'll concede what's right in your closing, then explain why the last third of a position still doesn't clear the bar.

1. What I'm conceding¶

"Year-end settling" is a coherent reading. My Q1-versus-Q4 test only disproves "Q4 was a new run-rate." It doesn't disprove a true-up.
My multiple rule wasn't binding. 20x is a 5.0% earnings yield, below the 5.21% Treasury, so the multiple depends on growth. I accept that. It's also why Q2 matters, because Q2 is the first test of whether revenue stops falling.
I paired corners. I've fixed it. At $1.75-1.80 and 15-18x, the one-off branch is $26-32, or about -12% with the dividend. Break-even confidence moves from 53% to ~50%. Matching the 10-year still takes ~71%.
Three-for-three gaps is not a forecast. It's a risk flag, and I'll treat it as one.

2. The "steady annual series" depends on the unexplained quarter¶

Your $2.00 uses FY26's 6.7% net margin, which includes Q4 FY26. If the bridge shows a one-off, that anchor is wrong. Your $1.90 applies a single quarter's margin to a full year.
Your mirror table also shows how noisy quarterly margins are. Q4 net margin was 1.9% in FY25 and 9.7% in FY26. Clean quarters ran 4.6-6.4%, a 180 bp swing between Q2 and Q3 alone. Against that noise, +60 bp of gross margin and +15 bp of net margin in one quarter is not evidence of stabilization.
Your own annual math lowers my durable branch. I gave you $2.04-2.07, but your reading is $1.90-2.00. At 17-20x that is $32-40, about +7% with the dividend, and break-even confidence rises to ~64%.

3. Pricing the tail¶

You said the starter buys a slice of the recovery tail, so I'll give the tail explicit weight. I'm using your 10% and treating the outcome as reachable within 12 months, which is generous. This is illustrative.

State	Probability	Total return
Bridge shows a one-off	55%	~-12%
Durable	35%	~+12% (my table; ~+7% on your EPS)
Half-recovery ($44 plus dividend)	10%	~+29%

EV is about +0.5%, or about -1% on your durable EPS. The 10-year yields 5.21% with no gap risk.

You also called the tail multi-year. If $42-46 takes three years (my assumption), that is 6-9% a year in price. The recovery gets weight in my tree, just not enough to matter.

4. Reading the bridge is not an edge¶

You said the 10-K and Q4 release already exist. They've been public for months, so the price, the 51% decline and the Street's $1.68 all reflect whatever they say. Reading them helps us estimate fair value but doesn't show the market is wrong.

If the bridge says "durable" and the Street still sits at $1.68, one of two things is true: - Analysts who cover NKE missed a document in their own filings. - They know something we can't see, such as guidance, that overrides it.

I won't bet on the first. The Street may be 4-7% light on clean math, but that is $0.07-0.12 of EPS, worth $1-2 at 15-18x. It isn't a contrarian setup.

5. Carry and calendar¶

"Mine gets paid while we wait" holds only if cash pays nothing. Ten weeks to the late-December print is: - ~1.0% in T-bills at 5.21%. - ~1.2% in dividends ($0.41 on $35.30).

The difference is about 16 bp, and the Treasury carries no gap risk or coverage question. Your own kill list includes "any change in dividend language."

The starter owns the wrong part of the calendar. Before Q2, the stock faces: - The late-October FOMC, with 82% odds of another hike. - The Nov 3 midterms. - Mid-November CPI. - The ~12/01 ex-dividend date.

None of these test the thesis. Q2 does. You say you'd cut ahead of the print if the tape hasn't confirmed. That means holding through the macro calendar and selling before the one catalyst that bears on revenue and gross margin.

You've also conceded that: - The first overhead levels offer about 0.7:1. - OBV is flat. - RSI is below 50. - Sizing doesn't create edge.

A third of a zero-edge bet is a smaller zero-edge bet. I agree with step 0 of your plan, and even on its terms it doesn't produce a reason to buy.

6. Where we end¶

Agreed: - The bridge is the gating item. - The dividend is under-covered at 66-86% of TTM FCF, with about $1.5B of the $2.1B coming from Q4 FY26. - There's no solvency problem. - This isn't a short.

Still disputed: whether to own a third before Q2. I say no.

My conclusion: NKE at $35.30 is fairly priced if the bridge is kind and expensive if it isn't, and it is never cheap. I'd pay up for evidence: - Q2 revenue decline narrower than -4.3%. - Q2 gross margin at or above 41.2%. - Positive FCF without a Q4-style swing. - A bridge showing Q4 FY26 was durable.

What would make me more bearish: - Q2 gross margin below 40.6%. - A second negative-FCF quarter. - Any change in dividend language. - A 10-year close above 5.31%.

Where I could be wrong: if the bridge is durable and Q2 confirms, I'll be buying higher. That is the price of evidence, and with EV near zero against a 5.2% risk-free rate I'm willing to pay it.

Recommendation: don't initiate before Q2. This is a hold/avoid for new money, not a short. Bear Analyst: # Bear Reply: The Bid Fixes the Price, Not the Edge

Bull, you caught real errors, and I'll own them first. Then I'll show what the corrections change and what they don't.

1. What you got right¶

The 5.21% is the 10-year, not a bill. The effective fed funds rate is 3.75%, so a 12-month bill is near 4%. Ten weeks of cash earns about 0.7% against the dividend's 1.16%. My 16 bp gap was wrong, and 45 bp is right.
The one-off multiple is a judgment call. I justified 15-18x with an earnings-yield rule I then conceded isn't binding. Your 17-20x isn't indefensible, and your tree arithmetic checks out (+4% against my -1% to +0.5%).
"Three for three" is a risk flag, not a regularity. I can't date the prints from this file.
A resting bid beats a market buy. It is the first version of the starter where price discipline does any work.

2. The hurdle is the bill plus a risk premium¶

Fixing the benchmark lowers my hurdle but doesn't remove it. A beta-1.1 stock should clear the bill by an equity premium. I'm assuming 4-5% for that, which is my assumption and not in the file. That puts the required 12-month return near 8-9%.

Tree	One-off multiple	EV (total return)	Shortfall vs. ~8-9%
Mine	15-18x	-1% to +0.5%	~8-10 pts
Yours	17-20x	~+4%	~4-5 pts

Even on your multiple, EV roughly equals the bill, which means a zero risk premium for an equity that gaps 7-15%. The bill correction trims about 1.2 points off my gap, not the whole gap.

The dividend also isn't extra. The price drops by $0.41 at the ~12/01 ex-date, so the yield is a component of total return and already sits inside both EVs. "It pays me while I wait" compares a piece of NKE's return to cash's whole return.

3. Why I won't put 20x in the bad branch¶

At $35.30 the stock already trades at ~19.9x clean EPS of $1.77. Putting 17-20x on the one-off branch makes the bad state a roughly -2% outcome by construction, so the tree can't show downside.

That branch is the one where: - Revenue has fallen five quarters running. - The payout is ~92% of clean EPS ($1.64 / $1.775). - Only the one unexplained quarter lets FCF cover 66-86% of the dividend.

A growth multiple needs growth, and that branch is defined by its absence.

Since the bridge is public, $35.30 already embeds someone's answer. Both trees therefore measure how much we trust the market, not an edge over it. My case isn't that NKE is overpriced. It is that nothing in this file shows it underpriced, and the position carries event risk.

4. Where the $34 plan leaks¶

$34 is only 1.2 ATR away. ATR is 1.06, about 3% of price, so the bid will probably fill within ten weeks. It will also fill on paths that continue to 32.
"Defended once" is generous. The tape traded 31.97 on 10-02, 5.6% below the 33.87 close. Bollinger bands are a moving statistic, not a horizontal level. Two weeks of closes after one capitulation day isn't a tested floor.
The ratio table doesn't hold together. The denominator (31.97) is "a thesis check, not a loss limit," and the numerators (36.38, 37.59) are "checkpoints, not targets." The 1.2-1.8:1 ratio uses a floor you won't enforce and a ceiling you won't aim for.
Your fill conditions collide with your deferral rule. Hot CPI, hike odds and a 10-year near 5.3% are the likeliest routes to $34, and they also trigger your "defer above 5.31%" rule.
The December trim can't fail on the bridge. Step 0 requires a favorable bridge before the starter exists, so the starter is held into the print by construction. That is the event risk we've been arguing about.
The June window wasn't benign. The stock went from $46.18 (6/12, the McCartney sale price) to a $40.32 close on 6/26, down 12.7%. You said you can't call that print benign, and I agree. If that window held the Q4 FY26 report with the 49% gross margin and $1.07B of net income, the market sold the "good" numbers. Dates are inferred, but it fits a market that had already discounted the number or saw guidance we can't.

5. $2.04 came back¶

Your "what survives" section prices the true-up reading at "$1.90-2.04." We agreed two rounds ago that $2.04 requires Q4 FY27 net income near $1.0B. Without it: - The true-up range is $1.90-2.00, or 17.0-17.9x at $34. - $2.00 uses FY26's 6.7% margin, which includes Q4 FY26. - $1.90 applies one quarter's margin to a full year.

You conceded neither is independent. So at $34 you pay the lower third of your own durable range. That is fair value, not a discount.

6. Your question: bridge shows a true-up, stock at $34, do I buy?¶

Yes, a small starter. At $1.90-2.00 and 17-20x, the durable branch spans about -0% to +22% with the dividend, midpoint ~+11%. That is a thin pass over my 8-9% hurdle, before any weight on the tail.

Two caveats keep this from being a bull win: 1. Reading the bridge is a filter, not an edge. It keeps you out of the ~55% branch where you'd own it for no reason, and I'll credit that. But the Street has the same document and still sits at $1.68. 2. Neither of us has read the bridge. My answer is conditional on a document absent from both our toolkits.

So the debate has narrowed to timing and process. We hold nearly the same odds (55% vs. 55-60% one-off).

7. Where we end¶

Agreed: - The bridge is the gating item. - There is no solvency problem. - The dividend is under-covered at 66-86% of TTM FCF, with ~$1.5B of the ~$2.1B from one unexplained quarter. - This isn't a short. - A market-price starter has poor risk/reward.

Still disputed: - Whether a resting $34 bid is a margin of safety or a modest discount that fills in the wrong paths. - Whether a starter should be held into a print that has been followed by lower prices.

My recommendation hasn't changed for the decision at hand. With the bridge unread, don't initiate at $35.30. A bid at $34 is admissible only after the bridge is read and shows a true-up, sized small, and I'd want it exited or hedged before the print. Absent that, wait for Q2 evidence: a revenue decline narrower than -4.3%, gross margin at or above 41.2%, and positive FCF without a Q4-style swing.

What would make me more bearish: - Q2 gross margin below 40.6%. - A second negative-FCF quarter. - Any change in dividend language. - A 10-year close above 5.31%.

Where I could be wrong: if the bridge is durable and Q2 confirms, I'll have bought higher than your bid. With EV at or below the hurdle and the key document unread, I'll pay that price for evidence.

Recommendation: hold/avoid for new money, not a short.

Research Manager¶

Recommendation: Underweight

Rationale: This debate converged more than most. By the end, the two sides agreed on the facts. There is no solvency problem: $6.9B cash, a 2.07 current ratio and 0.73x D/E. It isn't a short. The dividend is under-covered at roughly 66-86% of TTM FCF, and about $1.5B of the ~$2.1B TTM FCF comes from one unexplained quarter (Q4 FY26, with a derived 49% gross margin and $1.07B of net income). Both sides also agreed that reading the Q4 FY26 bridge in the 10-K is the gating item and that buying at the market price ($35.30) has poor risk/reward, about 0.3-0.7:1 to the first overhead levels against 31.97. So what remained was whether the risk-adjusted expected return is good enough to own the stock, and the bear won that on substance. The bull walked back most of the core claims. Priced for permanent decline was conceded as overstated. The $2.04 EPS turned out to need a ~$1.0B Q4 repeat. The two-quarter FCF improvement leaned on the same anomalous quarter. And the bull admitted to having no demonstrable 12-month EV edge. What the bull kept is real but thin: Q1 FY27 gross margin up ~60 bp YoY to 42.8%, total costs falling 4.5% in dollars on revenue down 4.3%, earnings decline slowing from -32% to -2%, a solid balance sheet, a ~4.6% yield, and a small recovery tail (~$42-46 on a half-recovery). Against that, the bear's points held up. Revenue growth has decelerated five straight quarters (+1.1% to -4.3%). Clean-quarter EPS of about $1.75-1.80 puts the stock near 20x for a shrinking business. Q1 FY27 gave back 640 bp of gross margin versus Q4 FY26 on higher sales, which leans toward the Q4 spike being a one-off. Both sides put that branch at 55-60%, the majority case. The tape apparently gapped down 7.4% on the heaviest volume in the sample after the Q1 print that the bull calls stabilization, and it is still in a downtrend on every higher timeframe with flat OBV and RSI below 50. Even after the bull's fair corrections (the bill, not the 10-year, is the cash hurdle, and 17-20x in the bad branch is arguable), the trees produce EV of about -1% to +4%. That is roughly the bill yield and well short of a bill-plus-equity-premium hurdle of around 8-9%. The dividend is already inside that total return, not extra. Macro adds pressure: the 10-year is at 5.21%, odds of another hike are 82%, oil is near $103, and the late-October FOMC, Nov 3 midterms, mid-November CPI and a late-December Q2 print all come before the thesis can be tested. I'm not going to Sell, because the balance sheet, cost flex, washed-out sentiment and a plausible year-end true-up reading of Q4 make outright exit or shorting a poor bet. But this isn't balanced enough for Hold. The majority-probability branch is negative, the positive branch only gets to fair value, and key evidence is missing: the Q4 FY26 bridge, guidance, inventory, segment and China data, and confirmed print dates. So I'm calling it a cautious Underweight: trim, don't buy at $35.30, and let Q2 and the bridge earn the position back.

Strategic Actions: 1) Target weight: about 0.5x a standard allocation (range 0.4-0.6x). No new money at $35.30. 2) Trimming existing positions: rest limit sells in the 36.4-37.6 zone (daily SuperTrend flip at 36.38, 50 SMA at 37.59) to sell into the current bounce rather than into weakness. If there's no bounce, finish the trim in tranches by about Dec 1, before the late-December Q2 print. Don't dump into a gap. Spread the sells across sessions, and remember that stop orders won't protect against 7-15% gaps. 3) Gating item: read the Q4 FY26 bridge in the 10-K (we did not have it). If it shows a one-time gain or accounting plug, cut to about 0.25x or exit, since clean EPS of ~$1.75-1.80 at 15-18x implies ~$26-32. If it shows a genuine year-end true-up with ~$1.90-2.00 normalized EPS, holding 0.5x is fine. New money may then use the bull's resting limit bid at ~$33.8-34.2 (lower Bollinger band 33.82, 10-02 close 33.87), but only to top up to the 0.5x cap, not above it. Defer any buying if the 10-year closes above 5.31%. 4) Event risk: if you carry exposure into Q2, hold no more than 0.5x. If listed options are available (pricing isn't in our data), consider a protective put or collar on the residual position before the print. 5) Upgrade triggers (to Hold, then Overweight, rebuilding toward 1.0x in thirds): Q2 revenue decline narrower than -4.3%, Q2 gross margin at or above 41.2% (+60 bp YoY holds), positive FCF without a Q4-style working-capital swing, and a weekly close above 37.59 with RSI above 50 and OBV confirming. 6) Downgrade triggers (cut to 0.25x or exit): Q2 gross margin below 40.6%, a deeper revenue decline than -4.3%, a second negative-FCF quarter, any change in dividend language, a daily close below 31.97 on heavy volume, or a sustained 10-year close above 5.31%. 7) Data gaps to fill before resizing: the Q4 FY26 bridge, management guidance, inventory and segment/China detail, actual earnings dates, and current T-bill yields. Our dividend amounts and ex-date (~12/01) are inferred, not taken from filings.

III. Trading Team Plan¶

Trader¶

Action: Sell

Reasoning: The research plan's Underweight maps to a Sell, meaning a trim rather than a short. Both sides agreed the expected value is roughly -1% to +4%, about the T-bill yield and well short of an 8-9% hurdle, and the majority-probability branch (the Q4 FY26 spike was a one-off, clean EPS ~$1.75-1.80, ~20x for a shrinking business) is negative. The technicals agree: SuperTrend is down on the weekly, monthly and daily tiers, price is 6.1% below the 50 SMA and 24.7% below the 200 SMA, OBV is flat while price bounced ~3.9%, and RSI (43.82) is below 50. Volume has faded to 19.4M, and the three-day flat consolidation looks like a relief bounce rather than accumulation, so selling into it near 36.38-37.59 beats selling into weakness. The balance sheet (cash $6.9B, 2.07 current ratio) and washed-out sentiment argue against a full exit, and 10-02 showed a ~7.4% gap that ATR-based stops would not have caught, so the trim should be done in tranches. The Q4 FY26 bridge, guidance, inventory, segment/China data and earnings dates are all missing from the evidence, and the plan flags the bridge as the gating item.

Entry Price: 36.4

Stop Loss: 37.59

Position Sizing: Portfolio holdings were not provided, so size relative to the existing position: trim toward ~0.5x a standard allocation (range 0.4-0.6x) and add no new money at 35.30. Rest limit sells at 36.4-37.6 (daily SuperTrend flip at 36.38, 50 SMA at 37.59) and spread them across sessions in tranches, finishing by about Dec 1 if there is no bounce. Cut to ~0.25x or exit if the Q4 FY26 bridge shows a one-time gain or on a daily close below 31.97 on heavy volume. A weekly close above 37.59 with RSI above 50 and OBV confirming invalidates the thesis (upgrade trigger). Do not rely on stop orders through gaps.

FINAL TRANSACTION PROPOSAL: SELL

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: I'll start with the obvious objection, because I expect it from both of you: "Sell a stock that's already down 50% from its 52-week high, with 4.6% yield, $6.9B in cash and washed-out sentiment? That's the textbook place to be patient." I think that's the comfortable answer, and it's wrong here.

Start with what you're being paid to hold this. The expected value in the research plan is roughly -1% to +4%, which is about the risk-free rate with the Fed funds rate at 3.75%. For that, you carry a stock with a 3% daily ATR and three gap-downs of -10.5%, -15.5% and a 7.4% open on 142.7M shares in the last year. And the 4.6% dividend isn't the cushion people think. The 10-year Treasury yields 5.21%, so you'd get paid more to own the government. The payout is also uncovered: roughly $2.4B a year against $2.18B of FY26 free cash flow, with Q1 FY27 free cash flow at about -$64M. That's about 98% of forward EPS, paid out of a cash pile that's already $3B below its FY24 level. I'm not forecasting a cut, because nothing in the evidence says one is coming. But I won't call it a safety net.

The valuation case for patience is also weaker than it looks. Trailing P/E of 17x depends on a Q4 FY26 quarter with a 49.2% gross margin, when every adjacent quarter ran 40-43%, and $1.07B of net income against about $675M for the other three. If that was a one-off, clean EPS is around $1.75-1.80, so you're paying about 20x for revenue that fell 4.3% last quarter and sits 10% below the FY24 peak. I'll concede the bridge isn't in the evidence, and that's exactly why this is a trim to about half and not an exit. If Q4 turns out to be durable, I still own half. But I'm not waiting for permission to act on the more probable branch. And "down 80% from the high" is an anchor on a 2021 price. It tells you nothing about what the business earns today.

For the contrarian bulls, I'd go through your evidence one piece at a time. The weekly and monthly TD-9 buy setups are real, but they have no confirmation signal and may be provisional until the bars close. Insiders did buy, about $9.2M, but they're 17% underwater on the April buys and about 40% underwater on December, and nobody has bought in six months. Insider buying has been a poor timing signal here. The "washed-out sentiment" point is also weaker than it looks, because estimate revisions are still falling. BofA downgraded and HSBC cut to $34, which is below spot. Stocks rarely bottom while the targets are still being marked down. And I'm not leaning on StockTwits, since 17 of 18 messages are one put-holder talking his book. I'd ask you not to lean on the one "hung tough on a red day" post either.

On the technicals, the stock is below the 50 and 200 SMA with the 50 under the 200, and SuperTrend is down on all three tiers. OBV hasn't moved while price rose 3.9%, and volume has faded to 19.4M, the lowest since August. That's a relief bounce, not accumulation. ADX falling from 36.7 to 22.4 is just a gap impulse being absorbed. It doesn't signal a reversal. And if the daily SuperTrend flips at 36.38, the weekly stop is still at 42.88, and higher tiers outrank lower ones.

The macro makes this worse. 97% odds of no cuts in 2026, 82% odds of another hike, a 10-year above 5%, oil near $103. Recession odds are only 8%, so there's no flight-to-quality bid coming. What hurts is valuation compression on long-duration turnaround stories, and NKE is exactly that.

Now the objection from the other direction, which I expect from the conservative side: "Sell it all now, at market." I'd say no, and the reason is price. Selling at 36.4 against a 37.59 invalidation line and a 31.97 downside marker gives about 4.4 points of downside against 1.2 of risk, nearly 3.7 to 1, and still above 2 to 1 if you only target the 33.85 area. Selling at 35.30 turns that into roughly 1.5 to 1. The ladder into 36.4-37.6 is what makes the trade good, and the Dec 1 deadline caps the cost if the bounce never comes. Keeping 0.4-0.6x also preserves a cheap option on the turnaround, paid for by selling the bounce. A full exit gives that up, and I'd only go to 0.25x or out if the bridge shows a one-time gain or we close below 31.97 on heavy volume.

To the neutral side, "wait for the Q4 bridge and earnings" sounds balanced, but the last three big drops arrived as gaps, and stops won't catch those. Waiting means taking another gap without compensation, with the next scheduled report likely late December and not yet in the evidence. Selling in tranches ahead of it is how you reduce exposure to that event without paying for it.

The bold part of this plan is being willing to cut a stock when the retail story says it's too cheap to sell, and doing it at a price that makes the math work. I'm sticking with Sell. Aggressive Analyst: Several of my lines didn't survive your arithmetic, so I'll fix those first.

Neutral is right that my 3.7 to 1 leans on a single intraday print at 31.97. The honest figure is about 2 to 1 on 33.85 from a 36.4 sale, and about 0.6 to 1 at market. I'm also dropping "cheap option," because a long with no floor isn't one. I'm dropping "stocks rarely bottom while targets are cut" too, since price often turns before revisions and my case doesn't need it. The 17x versus 20x argument goes as well. The market already pays 21x forward EPS of $1.68, so clean earnings aren't news the price is ignoring. The multiple says the stock is priced for a recovery that revenue down 4.3% hasn't delivered. That's a reason not to add, not proof that selling is right.

The earnings-cadence point is the best contribution in this debate, and it weakens my claim that waiting means taking another gap. If those gaps were report reactions, the next one is probably mid-to-late December, so I overstated the hazard for the next six weeks. I'd still hold the inference loosely. The October 1 bar carried 112M shares before the October 2 gap, which isn't what a clean after-the-close report looks like, and the August 17 break came on 58.7M shares with no report. Unscheduled risk is smaller, not zero. Still, nothing forces a market order at the midline with the daily z-score at -0.06.

Conservative, your front-loading cost is mispriced. The 1.5% is the cost of selling the whole half at market, and only in the roughly 57% of paths where the ladder would have filled. On Neutral's math, a one-third slice at market costs about 0.5% in those paths and saves about 0.7% in the rest. That's near zero in expectation, so what you're buying is variance reduction. Neutral's first rung at 35.8 to 36.0 buys the same thing for about a quarter percent and fills about seven times in ten before the lower band. I'm adopting that rung and the thirds, because it's a better plan than mine. Paying double to feel safer isn't bold. Neutral also caught a tension in my position, since a strong negative-drift view argues for faster execution. But my view is a tilt, not a conviction. An expected value of -1% to +4% is a no-edge view with a skew, and the first rung is the right compromise for that.

Your gap math also needs a correction. The 3.7% on the half for the smallest repeat uses the 7.4% open gap. On October 2 the stock opened at 32.55 but closed at 33.87 against a prior close of 35.15, which is 3.6% close to close. That scenario is closer to 1.8% on the half. The 10.5% and 15.5% gaps were close to close, and they're real. The half I keep takes that risk, and I'm choosing it knowingly. Your point about the December 1 deadline is fair: it caps time, not cost. But with thirds, only the last sixth of the original position is ever sold into weakness at the deadline.

The macro calendar, with the FOMC, the midterms and CPI, argues about the size of what I keep, not the speed of getting there. The retained half sits through every one of those dates either way. The rate headwind works on the multiple slowly, and beta of 1.10 doesn't capture that.

Why keep a half at all? Nobody here has an edge to be fully out. The weekly and monthly z-scores are -1.30 and -1.56, both TD-9s are complete, and the plan's own range tops out at +4%. The option I wanted is in the cash, not the shares. Sell the bounce into bills, and if December shows margins holding and revenue stabilizing, buy back after the gap with information, possibly below where I sold. If it doesn't, I sold the bounce. The price is forgone upside on the sold half. A collar on the retained piece would cap the upside that's the only reason to hold it, and a put spread leaves a 15% gap partly uncovered. Neither of us has seen option prices, and the cheapest protection is the smaller position. I'd revisit a hedge only if a large piece is still held heading into December.

On triggers, 31.97 is too far and I concede it. A close below 33.82 is only about 1.4 ATR away, and the stock closed at 33.87 eight sessions ago, so I'd rather not cut on one noisy print. I'd cut toward 0.25 to 0.3x on a second close below, or one on expanding volume.

On the bridge, I'll pull it this week, but the run rate is already visible. If 49.2% gross margin were the new normal, Q1 FY27 should show it. It printed 42.8% and $712M, in line with the adjacent quarters and the $1.68 forward EPS. One quarter isn't conclusive, so the filing still has to say why. But I'd want a structural explanation before going to 0.6x. This also makes 0.4 versus 0.5 moot, since the filing will be read well before the upper rungs could fill.

So I'm still at Sell, as a trim in thirds. The first rung goes at 35.8 to 36.0, the second at 36.4 to 36.9, and the third at 37.2 to 37.6. The working target is 0.5x of a standard allocation, with no new money at 35.30 and stragglers finished by December 1. Proceeds go to bills, and a weekly close above 37.59 with RSI over 50 and OBV confirming stops the selling. All sizing is relative to a standard allocation, since I don't know the actual position. If you hold nothing, this simply means don't buy here. Aggressive Analyst: Most of this is settled, so I'll say where you've moved me and then argue the few places I still disagree.

Conservative, you're right on the first sixth, and I was wrong to call it paying double to feel safer. Neutral's numbers settle it. A resting order at 35.9 fills about seven times in ten and gains about 0.3% of allocation, and the other three times the unsold sixth ends up about 0.7% worse. That's a wash, which is what any limit order on a driftless walk gives you. The rung only wins if the bounce keeps going, and I've spent two rounds arguing it won't. Your decomposition also lands. The three gaps compound to about -27% and the stock is down 51%, so ordinary days did roughly half the damage. I can't justify leaving a sixth sitting above the market while that drift goes on, so I sell it now. This changes the trader's 36.4 entry for that sixth only.

The upper rungs aren't a discount either, but they aren't a plan to wait for a rally. They're one door of two. If price rallies into 36.4 to 37.6, I sell there. If it breaks down, the triggers sell. Either way I end near 0.5x, and the Dec 1 deadline covers the path where it goes nowhere. The old 37.59 "stop" is really the line where I stop selling and reassess, since this is a trim and not a short.

On the triggers I'm with Neutral. After one sixth is sold I'm at about 0.83x, so a single close under 33.85 taking me to 0.4x means selling about 0.43 of the position at the next open. A bounce to 35.30 then costs about 2% of allocation. Your own argument was that whipsawing a sixth costs a few tenths of a percent, and that favors sixth-sized slices. The first close under 33.85 sells a sixth. A second close, or an expanding-volume close, sells another. A heavy-volume close under 33.82, or a bad filing, goes toward 0.3x. You're also right that a reactive order fills at the next open, so my close-to-close correction doesn't help a seller. I'll stop leaning on it.

On 0.4x versus 0.5x, three sixths leave you at 0.5x, so 0.4x isn't a default. It's an extra tenth the filings have to earn. Your cash-flow arithmetic is right, and I'd been using the full-year figure. Q4 FY26 free cash flow was about $1.5B against $685M for the nine months, so without it the run rate is under $1B annualized. Q1 operating cash flow was $135M against $222M a year ago. But FY25's Q4 was only about $363M, so a big Q4 isn't seasonal, and it's the same quarter with the 49.2% gross margin. That makes inventory and working capital the lines to read in the 10-K, and the CFO change gets an 8-K check. It kills the 0.6x branch for me. It doesn't take me below 0.5x by itself, with $6.9B of cash against a $2.4B payout. I'm still not forecasting a cut, but I'd add the dividend declaration ahead of the Dec 1 ex-date to the calendar.

On December I'll take Neutral's rule over Conservative's number. You're right that if I plan to rebuy after the gap, the half I hold through it is the half I hold without the information. But a 10% move on a half is a tail, and you're comparing it to an expected value. The tail has two sides, and the last three being down tells us to respect variance, not which way it goes. So I'll price the January put spread this week with the strikes you described and decide before the print. If the filings are clean and the quote is fair, I hold the half. If the filings are murky or the quote is rich, I sell another sixth, because implied vol into an earnings date charges you for exactly the gap you're hedging, and selling has a known price. I still wouldn't use a collar, since it caps the upside that's the only reason to hold the half.

Neutral asked for the rebuy rule in advance. These thresholds are my judgment, not derived from the evidence. If the next report shows revenue declining by less than Q1's 4.3%, gross margin around 42% or better with no one-time item, and operating cash flow back to positive, I rebuild toward a standard allocation in steps. I do that whether or not the price is above where I sold, because that is the cost of having been out for the gap. If revenue is worse or margin slips below about 41%, I stay at or under 0.5x.

The plan, then, sizing relative to a standard allocation since we don't know the book. I sell the first sixth now, read the 10-K, 10-Q, Q1 release and call this week, and then rest the other two sixths at 36.4 to 36.9 and 37.2 to 37.6. The downside slices fire as described. I aim for 0.5x and go to 0.4x only if the filings say so. I add no new money at 35.30, park proceeds in bills, finish by Dec 1, and stop selling on a weekly close over 37.59 with RSI above 50 and OBV confirming.

What survives from my first round is that the cash is the option, not the shares. Selling a bounce into bills costs me some upside on the sold half. That's a cheaper price than carrying full gap exposure at 21x forward earnings while revenue is still falling. It's still a Sell, as a trim. If you hold nothing, it simply means don't buy here. Aggressive Analyst: Most of the plan is settled, so I'll take what I'm conceding first, then argue the three places I still disagree.

Conservative, you're right about my rebuy rule. Q1 operating cash flow was positive at $135M. What went negative was free cash flow, about -$64M, because capex was $199M. I named the wrong line. But I'd take Neutral's fix over yours. Requiring 42.8% gross margin in Q2 asks for a 220 basis point jump from last year's 40.6% quarter, which is a seasonality error, not discipline. So I rebuy when gross margin is up year over year, the revenue decline is narrower than Q1's 4.3%, free cash flow is positive, and the outlook hasn't been cut. I rebuy in sixths, not all at once.

You're also right on two other things. The hedge decision belongs in the first half of November, because event premium is fattest at the print. And the dividend declaration is a dated event we hadn't calendared. Your gap math holds too. At 0.83x, a repeat of the 10.5% gap costs about 8.7% of an allocation, and the downside slices don't change that, because a close under 33.85 comes after the gap. Slices manage drift and only size manages gaps. That's the case for Neutral's clock, which I'm adopting. The second sixth goes at market by mid-November and the third by December 1. There is one budget, so each sixth is sold once, whichever door or clock gets there first.

Neutral, you're right on the bridge. The trader's trigger to cut to 0.25x if Q4 was a one-time gain is retired. The price is 21x a forward $1.68 that Q1's $0.48 already supports, so confirming the one-off isn't news. While reading the filings, check what the stock did the day Q4 was reported. I can't tie a date to it from the evidence, but the tape went from 46.18 on June 12 to a 40.32 close on June 26. If that was the reaction, the market saw a 49% gross margin and sold it, which says more about what it believes than a footnote will. I'm also keeping your earnings-cadence inference loosely. October 1 carried 112M shares before the gap, and August 17 broke on 58.7M with no report in our evidence.

Now the disagreements. First, Conservative, selling the next sixth at market because the filing calls Q4 a one-off is trading on news already in the price. If what you want is a third, argue it as a size, not as a reaction to a filing. And the target has ratcheted from 0.5x to 0.4x to a third while the tape sits at the Bollinger midline with a daily z-score of -0.06. Your cash-flow subtraction was real new information, and it moved me off 0.6x. It doesn't move me below 0.5x, with $6.9B of cash against a $2.4B payout.

Second, our sixths land on 0.83, 0.67, 0.5 and 0.33, so let's stop quoting 0.4x and 0.25x. The base is a half and the floor is a third. The floor moves only on a new fact, such as a dividend warning or a heavy-volume close under the 31.97 low, which would break the whole range.

Third, December. "No edge, so variance is unrewarded" argues for zero, not a third. The case for keeping something isn't edge, it's two-sidedness. The weekly and monthly z-scores are -1.30 and -1.56, and both TD-9 setups are complete. Q1 gross margin rose 60 basis points on falling revenue, and directors and the CEO put $9.2M in at much higher prices. None of that proves a bottom, and the insiders are 17% to 40% underwater. But a half carries about 7.8% of an allocation on a repeat of the 15.5% gap, and that is survivable. So I take Neutral's test, written down now so it isn't a feeling in December. Hold the half through the print only if three things hold. The Q1 outlook is consistent with $1.68, the dividend is declared unchanged, and the January put spread quote is inside a maximum premium I set before I look at it. If any one fails, sell the sixth. Nobody has seen option prices, so I won't pretend the quote is cheap. I still wouldn't collar the half, since that caps the upside that's the only reason to hold it.

Here's the plan, sized against a standard allocation since we don't know the book:

Sell the first sixth now, around 35.30, and add nothing.
This week, read the 10-K, 10-Q, Q1 release and call. The items to read are:
outlook language
inventory and working capital, behind operating cash flow of $135M versus $222M on flat earnings, and behind Q4's roughly $1.5B of free cash flow versus $363M a year earlier
dividend wording
the reason for the CFO change

A bad read sells the next sixth at market that day. 3. If the read is clean, rest the second sixth at 36.4 to 36.9 and the third at 37.2 to 37.6. 4. The clock sells the second sixth by mid-November and the third by December 1. 5. The downside slices sell a sixth on the first close under 33.85 and another on a second close or an expanding-volume close. 6. Price the put spread this week, and apply the hold test in the first half of November. Confirm the actual report date, since it isn't in our evidence. 7. A weekly close over 37.59 with RSI above 50 and OBV confirming cancels the clock and any extra sixth. 8. Proceeds go to bills.

If you hold nothing, it simply means don't buy here.

It's still a Sell, as a trim. The cash is the option, and I'd rather meet December holding bills and a half-sized position I can afford to be wrong on than hold full size on a hope. Aggressive Analyst: Since this is the last pass, I'll say what I'm taking from each of you, where I still see holes, and then put the plan in one place so it can be executed.

Conservative, you're right that the hold test as written couldn't fail. I'm taking Neutral's repair. Write down today's forward EPS of $1.68 now, and a drop of a few percent from it by the early-November decision date is a fail. The tolerance is my judgment, not a derived number. Vendor forward estimates may lag this week's BofA and HSBC moves, so a late drop counts as information. You're also right that a pass on the hedge means you buy the spread, not that you admire the quote. And a flat $0.41 is a pass, a cut or hedged wording is a fail, and a raise earns nothing extra on a payout near 98% of forward EPS.

On the reclassification, I'd note that it makes the bridge less valuable. A reclassification big enough to turn a 40-43% margin into 49% would also show up in Q1's 42.8%, and it doesn't. So Q4 is either a one-time item or an artifact of deriving it as annual minus three quarters. The price at 21x forward already treats it that way. A smaller reclassification could still contaminate the 60 basis points, though. So I'm dropping that number from my reasons to keep a half until the filing says the comparison is like for like. My case for keeping a half doesn't need it.

Neutral, you're right on the June check. I raised it as something to look up, not a pattern, and "the market has sold four prints" rests on prices nobody has tied to a date. It doesn't count until the report date is confirmed, and that goes first on the reading list because the whole December schedule hangs on it. You're also right that slices are sixths of a standard allocation, not of whatever you hold. The target is a level, a half. Someone at 1.5x has six slices to sell, and someone at or under a half sells nothing and keeps only the downside triggers.

The plan now names "a sixth" at five different triggers, so I want to pin down the budget. Three sixths take you from a standard allocation to a half, and the rungs, the clock, the closes under 33.85 and a bad filing read are only ways of deciding when each of those three goes. A bad read pulls the next sixth forward and doesn't add one. A fourth sixth, taking you to the floor of a third, comes only from a failed hold test or a genuinely new fact. Failing two legs of the hold test is still one sixth. Below a third means re-underwriting, which is also what a close under 31.97 means.

On December, I'll accept the burden of proof. I have to be able to write one sentence on why the retained piece earns its variance, and it can't use "down 80% from the high" or "sentiment is washed out," since we've retired both. Mine is that the outlook fits the $1.68 the price already reflects, the dividend is intact, and this is the piece that participates if December gaps up. If I can't write that on the decision date, the sixth goes. That's a stricter standard than I started with, and I'm fine with it. I still wouldn't collar the half, because that caps the only upside that justifies holding it. If the retained piece is too small for a clean 100-share spread, selling is the cleaner hedge.

On the rebuy, I'll take the cap of two sixths back after any single print, since one print is one observation by the same standard we applied to the gaps. The rest waits for a second confirming quarter. A weekly close over 37.59 ends the selling and rebuys nothing, because the weekly SuperTrend sits at 42.88 and higher tiers outrank a bounce. If December gaps up and I rebuy above where I sold, that's the cost of having trimmed. I wrote that down already.

Conservative, you're right that gap scaling cuts both ways. If the allocation is small, rushing costs little and so does waiting. If the book is concentrated, the front-loaded sixth and the floor are the whole point. None of us can see the book, which is why everything is in standard-allocation terms.

Here is what I'd stand behind. Sell the first sixth at today's open with a marketable limit near the 35.30 close, resting nothing above the market for it, and add no new money. This week, confirm the report date and read the 10-K, 10-Q, Q1 release and call. The reading list is: - the outlook language - inventory and working capital behind $135M of operating cash flow - dividend wording - the CFO change - whether the margin comparison is like for like

A bad read sells the second sixth at market that day. A clean read rests the second at 36.4 to 36.9 and the third at 37.2 to 37.6. The first and second closes under 33.85 each sell a sixth, the clock sells the second by mid-November and the third by December 1, and a weekly close over 37.59 with RSI above 50 and OBV confirming stops the selling.

In the first half of November, run the forward-EPS and outlook legs and buy the spread if the quote is inside a cap written down before looking. The dividend declaration is a tripwire, and a cut or hedged wording sells a sixth that day. Proceeds go to bills.

It's still a Sell, as a trim. I'd rather meet December holding bills and a half-sized position I can afford to be wrong on than carry full gap exposure at 21x forward earnings while revenue is still falling. If you hold nothing, it just means don't buy NKE here.

Conservative Analyst¶

Conservative Analyst: I agree with the direction, and that shapes where I push back. By your own numbers, holding has an expected value of roughly cash, -1% to +4% against a 3.75% policy rate, and you carry a 3% ATR and a history of gaps to earn it. When expected return is a wash with cash, the case for selling is variance reduction. That's why I don't think the plan as you've defended it goes far enough, or reduces risk as reliably as you say.

Take the 3.7 to 1 ratio. That's a yardstick for deciding whether to open a new position. This is an existing holding, and the question is how much risk to keep. Per unit of a standard allocation, selling the whole half now at 35.30 instead of 36.40 costs about 1.5%. A repeat of the smallest of the three gaps on that same half costs about 3.7%, and a repeat of the 15.5% gap costs about 7.8%. You're counting the 1.10 you'd give up as a loss and treating gap risk as something stops will handle, when you've told us stops won't. Paying 1.5% to take part of that off the table isn't the weak trade.

The ladder also depends on the path. You describe the bounce as relief, with OBV flat and volume at its lowest since August, and there's a 35.5 to 36.4 closing cluster overhead that can act as supply. If you're right, price can stall under your limits while the full position sits through the late-October FOMC, the November 3 midterms, mid-November CPI, and a ten-year that peaked at 5.31% on October 5. You cite that macro as a reason to sell and then spread the selling across the weeks when it plays out. The December 1 deadline also doesn't cap the cost. It caps time. If the bounce never comes, price went lower, and the deadline sells you there.

I also can't accept calling the retained 0.4 to 0.6x a cheap option. An option has a known premium and a floor. This is a long position with no floor that has gapped 7% to 15% three times in a year. Selling the bounce doesn't pay for that. And you've said the dividend isn't a safety net: it's uncovered, the yield is below the ten-year, and Q1 free cash flow was negative. So the retained half carries thin cushion and full gap exposure.

Your escalation trigger is also too slow. A heavy-volume close below 31.97 is 9.4% below today's price, and this stock has gapped through levels before. A close below 33.82, the lower Bollinger band and essentially the October 2 closing low of 33.87, is about 4% away. That's the line where I'd cut to the lower end of the range.

On "more probable branch," I'm happy to lean on that judgment but not to size to it. The bridge, guidance, inventory, segment and China data, and the earnings date are all missing, and you've conceded as much. The bridge is the cheapest of those to resolve, because it's in the public 10-K and 10-Q. Pull it this week and tie the second half of the trim to what it shows.

I'm not asking for a full exit at market, since you anticipated that. The weekly and monthly TD-9 setups, a price about 10% off the low, and washed-out positioning are fair reasons not to dump everything into the thinnest tape since August. My adjustment is smaller and front-loaded:

Now: sell roughly a third to half of the intended trim at market, so part of the risk reduction doesn't depend on a rally.
Ladder: keep the remainder at 36.4 to 37.6.
Target: plan around 0.4x rather than 0.5x until the bridge is read.
Escalation: cut toward 0.25x on a close below 33.82, or if the bridge shows a one-time gain.
No new money: add nothing at 35.30.
Hedging: if the book can use options, a put spread or collar on what's kept is the only thing that actually works through a gap. I haven't seen option prices, so I can't say it's cheap.

I'm accepting two costs. One is some forgone bounce. The other is the roughly $0.41 dividend on shares sold before the likely December 1 ex-date, if the past pattern holds. All sizing here is relative to a standard allocation, since I don't know the actual position.

When the neutral analyst weighs in, I expect the case for waiting on the bridge. Get the bridge now, but waiting for information isn't a sizing plan. Conservative Analyst: Aggressive, you're right that for someone who sat through October 2 the loss was 3.6% close to close, not 7.4%, so my gap-on-the-half figure was too high. Neutral, you're right that the stock marks down by the dividend on the ex-date, and that thin tape doesn't matter at normal size. I'll stop making those arguments, and I'm glad the 3.7 to 1 and the "cheap option" language are gone. What's left is smaller, but it matters, and it's about things the converged plan glosses over.

First, a resting limit order isn't a discount. It has the same average outcome with more variance. Aggressive, you called selling a slice now "paying double to feel safer." Use Neutral's numbers. The first rung fills about seven times in ten, and then you're roughly 0.3% of a standard allocation better off than selling that sixth now. The other three times in ten, the stock tags the lower band first and the unsold sixth is about 0.7% worse. Seven-tenths of 0.3 against three-tenths of 0.7 is a wash. The rung only wins if the bounce keeps going, and your whole first round said the bounce has flat OBV and the lowest volume since August. If you hold a negative tilt, as you said, the tie breaks toward selling now. Neutral, you called that slice "near zero in expected value with lower variance" and then recommended the rung anyway. The rung doesn't buy the same variance reduction, because it's missing in the three paths where you needed it.

Second, "only the last sixth is ever sold into weakness" is true only on the quiet path. Your escalation rule is a plan to sell into weakness. A second close under 33.82, or one on expanding volume, takes you to 0.25 to 0.3x. If that fires with the first rung unfilled, you hold 1.0x and need to sell most of a half-plus allocation after two closes under the October 2 closing low. A reactive order gets the next open, not the close, so Aggressive's close-to-close correction cuts the other way for a seller. On Neutral's numbers, the stock touching 33.82 before 36.4 happens in about 43% of paths. Every sixth sold now is a sixth that doesn't get sold there. I'd stage the trigger to answer the whipsaw worry. The first close under the October 2 closing low, around 33.85, takes you to about 0.4x, and a second close or volume expansion takes you to 0.3x. Whipsawing on a sixth costs a few tenths of a percent. Being late on more than half the position costs a couple of percent of the allocation.

Gaps also aren't the whole story. By my arithmetic, the three gap days compound to roughly -27%, and the stock is down about 51%. So about a third of the decline came on ordinary days, like the August 17 break and the slide from the high 38s into the 35.5-to-36.4 cluster. A plan whose answer to drift is orders resting above the market is a plan that waits for a rally.

Third, the earnings-cadence idea is the best contribution here, but I'd draw the opposite conclusion for the half you're keeping. If gaps follow reports, the next one is mid-to-late December. Your schedule finishes selling on December 1, so the retained half goes into that print by design. The last three reactions were -10.5%, -15.5% and -3.6% close to close. That's three observations, not a distribution, and I'm not claiming the next one is down. But a 10% move on a half is 5% of an allocation, which is more than the plan's whole upside. Aggressive, you said you'd buy back after the gap with information. Then the half you hold through the gap is the half you hold without it. If the logic is "no edge, so cut variance when it's nearly free," that argues for entering December nearer 0.3 to 0.4x and rebuilding afterward.

You both said you'd revisit a hedge only if a large piece is still held in December. Under your own schedule it will be, so price a January put spread this week. I haven't seen quotes and won't call it cheap. But a spread struck from a few percent out to around 20% covers a 15% gap, so the objection is about strikes, not structure. And Aggressive, you said the cheapest protection is the smaller position. I agree, and that's the case for the low end of the range.

Fourth, the dividend and the "run rate is visible" claim. You used FY26 free cash flow of $2.18B against the $2.4B payout. Subtract the nine-month figure of $685M and about $1.5B of it arrived in Q4 FY26, the quarter whose margin you're both treating as suspect. That's my subtraction from the reported cumulative numbers, the same method the fundamentals report used for Q4 earnings. Without Q4, free cash flow ran under a billion annualized, and Q1 FY27 was -$64M. I'm still not forecasting a cut, and $6.9B of cash buys years. But a 4.6% yield below the ten-year, uncovered on the clean run rate, is thin cushion under the half you're keeping. The dividend declaration ahead of the December 1 ex-date is also a dated event that's on none of our calendars.

The earnings run rate is visible, but the cash run rate is weaker. Q1 operating cash flow was $135M against $222M a year ago while net income barely moved, and nine-month FY26 operating cash flow was down 62%. I can't see inventory, which is why it belongs on the reading list.

On that list, Neutral says guidance is the one missing piece. It's missing from our tools, but the Q1 release and call are public and carry the outlook. Add the CFO change too. The data shows Friend as CFO on August 5 and Denton on September 1, and the fundamentals report said to verify it. It may be innocent, but I want it explained before I go above 0.4x.

Here's where I land. It's still a Sell as a trim, sized against a standard allocation since I don't know the book.

First slice: sell the first sixth now rather than waiting for 35.8.
Other rungs: keep them at 36.4 to 36.9 and 37.2 to 37.6.
Target: 0.4x, not 0.5x, until the filings, release and call are read.
Downside triggers: staged at the first and second closes under 33.85.
Hedge: price the January put spread this week and decide before the print.
New money: add nothing at 35.30.
Proceeds: park them in bills.
Stop selling: if a weekly close clears 37.59 with RSI over 50 and OBV confirming.

If you hold nothing, it simply means don't buy here. Conservative Analyst: We're closer than the back-and-forth suggests, so I'll start with what I'm giving up. Neutral, you're right that my trigger was badly built. With one sixth already sold I'm at about 0.83x, so a single close under 33.85 taking me to 0.4x means selling roughly 0.43 of the position at the next open. A bounce the next day would cost about 2% of allocation, so sixth-sized slices are the right fix. You're also right that three sixths gets to 0.5x, not 0.4x, so the extra tenth has to be earned by the filings. Aggressive, I'll stop using the 7.4% open as the October 2 loss, since close to close it was 3.6%.

Here is where I think the plan still has holes.

First, the two resting rungs aren't a free choice. The arithmetic that made the first sixth a wash applies to them, and it's worse. On the same driftless back-of-envelope, a sale at 36.4 to 36.9 fills before the lower band only about 48 to 57 percent of the time. The top rung at 37.2 to 37.6 fills first only about 39 to 44 percent. For that last sixth, the lower band comes first more often than not, and then it gets sold after closes under 33.85, at the next open, in the low 33s or worse. All three of us hold a negative tilt, which lowers those odds further.

I'm not asking to sell everything today. I'm asking that the filing read change how you execute, not only the target. If the 10-K and 10-Q say Q4's 49.2% gross margin was a one-time item, the branch the trader called majority-probable is confirmed. Resting an order at 37.4 and hoping is the wrong response then. Sell the next sixth at market and work toward a third to 0.4x. Rest the rungs only if the margin is explained as durable, and since Q1 printed 42.8%, I'd treat that as the minority case.

Second, don't count the downside slices as gap protection. A gap shows up as the first close under 33.85, and the sale is the next open, after the gap. At 0.83x, a repeat of the 10.5% gap costs about 8.7% of an allocation and a repeat of the 15.5% gap about 12.9%. The triggers change none of that. They manage drift, and only size manages a gap. I'd also put every sixth, up-door and down-door, against one budget with a floor near a third of an allocation until the filings say otherwise. Otherwise a rally that reverses could ratchet us out near the lows.

Third, December. We all agree the retained half rides into that print by design. The rule is to hold if the filings are clean and the quote is fair, and to sell another sixth otherwise. I see two problems with it. "Filings clean" looks backward. The 10-K and 10-Q tell us what Q4 and Q1 were, not what Q2 FY27 will print. What bears on the print is the outlook in the Q1 release and call, so the rule should say to hold only if that outlook is consistent with the $1.68 forward EPS.

Deciding on the hedge "before the print" also means shopping for it when event premium is richest. Implied volatility generally builds into earnings, though I haven't seen quotes. So price it this week and decide by early November. And I'd flip the default. If expected return is about cash, the burden is on the retained sixth to justify its variance, so absent a positive reason, sell it before the print. Neutral, the tail has two sides, and I'm not arguing direction. I'm saying nobody has shown an edge that pays for that variance.

Fourth, Aggressive, your rebuy rule has a slip. You wrote "operating cash flow back to positive," but Q1 FY27 operating cash flow was already positive at $135M. What was negative was free cash flow, at about -$64M, because capex was $199M. "Gross margin around 42% or better" is also below Q1's 42.8%, so the rule could fire on a print worse than the one we just saw. Revenue declining by less than 4.3% is a thin bar after -1.1% in Q4 and -4.3% in Q1, though fine as a floor. I'd tighten it to free cash flow positive, margin at or above 42.8%, and a revenue decline narrower than Q1's. Otherwise you rebuy into the same risk you just sold.

So I'm still at Sell as a trim, sized against a standard allocation since we don't know the book. Sell the first sixth now. Read the filings and the Q1 outlook this week. If the margin is explained as durable, rest the rungs at 36.4 to 36.9 and 37.2 to 37.6. If it was a one-off or the explanation is murky, sell the next sixth at market and aim for a third to 0.4x. Fire the downside slices in sixths on the first and second closes under 33.85, against one shared budget with the floor above. Price the put spread this week, decide by early November, and default to selling the retained sixth before the print unless the outlook supports holding it. Add nothing at 35.30, park proceeds in bills, finish by December 1, and stop selling on a weekly close over 37.59 with RSI above 50 and OBV confirming. If you hold no NKE, this just means don't buy here. Conservative Analyst: Most of what's left is smaller than where we started, so I'll start with what I'm giving up.

Neutral, you're right that on a driftless walk a resting rung is a fair bet, so "the rungs fill less often" isn't an argument against them. I'm dropping it. You're also right about the bridge. At 21x a forward $1.68, the price already assumes the one-off branch, so a filing that confirms it tells us nothing new. Selling a sixth at market on that alone would be trading on priced news, so I retire the trigger. What can change size is your list: outlook language, inventory and working capital behind the $135M of operating cash flow, dividend wording, and the reason for the CFO change.

Aggressive, you're right that my target slid from 0.5x to 0.4x to a third, and 0.4x isn't even on a ladder of sixths. The base is a half and the floor is a third. The floor moves only on a new fact. I also take the year-over-year rebuy test over my 42.8% bar, which was a seasonality mistake. The one-budget rule and the clock are both fixes I should have proposed myself.

One caution before the bridge gets buried. The 49.2% margin is derived, annual minus three quarters, and the fundamentals report floated a cost reclassification as one possible cause. If that's what happened, the 60 basis points of year-over-year margin improvement may not be like for like. Both the keep-a-half argument and the rebuy rule lean on that number. The filing doesn't change my size, but one line of it should be read before anyone cites the 60 basis points again.

What remains is mostly the December test.

Right now the hold test is one you can't fail. Both of you say to hold the half if the outlook is consistent with $1.68. But $1.68 is presumably the market's number after the October 2 reaction to that very outlook, so it will match. The information is in what differs. Is forward EPS still $1.68 on the decision date in early November, after a downgrade and a target cut? Does the Q2 guide leave room to beat what's priced? Add forward EPS below $1.68 as a fail.

Aggressive's maximum premium set before looking at the quote is the right discipline, but say what a pass means. It means you buy the spread on the retained piece. If you only look at a good quote, the half goes through the print unhedged and the test was decoration.

Decide now what a flat dividend means. The evidence shows $0.41 on four straight ex-dates. I'd call flat a pass, a cut or hedged language a fail, and a raise no extra credit on a payout that's 98% of forward EPS and uncovered by free cash flow.

Aggressive, I'd add your June check to the reading list. If the slide from 46.18 on June 12 to the 40.32 close on June 26 was the Q4 reaction, the market has sold the last four prints, not three. That's still a handful of observations, not a distribution, and I'm not saying the next one is down. But it's the only repeating pattern in the data, so the hold test should pass on something forward-looking.

Neutral, you're right that gap losses are a percentage of the allocation, not the book. A repeat of the 10.5% and 15.5% gaps costs about 8.7% and 12.9% of an allocation at 0.83x, 5.3% and 7.8% at a half, and 3.5% and 5.2% at a third. But that scaling cuts both ways. If the stakes are small, rushing costs little too, so it can't break the tie toward going slow. If the book is concentrated, which we don't know, it argues for the floor.

On the rebuy, one print is one observation, the same standard we used to dismiss three gaps as a distribution. A revenue decline narrower than 4.3% is also the weakest form of improvement, because -4.2% passes it. I'd accept the rule with a cap of two sixths back after any single print. The rest comes after a second confirming quarter, or a weekly close above 37.59 with RSI and OBV confirming.

I still land on Sell as a trim, in sixths of whatever you hold now. The first sixth goes at the open at market or a marketable limit, not a resting order above the price. This week, read the filings for outlook, inventory and working capital, dividend wording, the CFO change, and whether the margin comparison is clean. A bad read sells the second sixth that day. A clean read rests the second and third at 36.4 to 36.9 and 37.2 to 37.6. Downside slices fire on the first and second closes under 33.85, all under one budget with a half as the base and a third as the floor. The clock sells the second sixth by mid-November and the third by December 1. The hold test applies in early November with the forward EPS check, the dividend rule, and a hedge you actually buy. If it fails, sell another sixth. Proceeds go to bills, and I'd confirm the report date first, since none of this timing is in the evidence. If you hold nothing, don't buy here. Conservative Analyst: I'll start with what I'm taking, because most of it is right.

Neutral, you caught me changing the unit. A sixth means a sixth of a standard allocation, not of whatever someone holds, and I accept that. You're also right that my "the market has sold four prints" line rested on two prices nobody has tied to a report date, so I'm withdrawing it. The report date goes first on the reading list, because the December schedule depends on it. I accept the split hold test too, with the dividend as a tripwire, since the declaration probably lands after the hedge decision.

I'll also give back part of my hedge argument. I said event premium would be fattest at the print, but a January expiry that spans the print already carries it. The better reason to decide in early November is that the filings and the outlook will have been read by then, and it keeps the decision out of the print week. I haven't seen quotes, so I won't claim more than that.

Aggressive, the budget is the cleanest version of the plan so far. Three sixths take you to a half, a fourth to a third, and each sixth is sold once whichever door gets there first. The forward EPS check with a tolerance also fixes the hold test I said couldn't fail.

I see four holes left, and the first is the most practical.

Both of you wrote a marketable limit near the 35.30 close. A sell limit at 35.30 is only marketable if the bid is at or above 35.30. If NKE opens at 34.80, which is under half an ATR below the close and well inside yesterday's range, that order sits unfilled above the market. That is the resting-order-above-the-price behavior we spent three rounds removing from the first sixth, and it fails in exactly the paths where selling now was supposed to help. Price it off the live bid when you enter it, a few cents through, or just use a market order. This stock traded 19 million shares on its quietest day since August, so a market order costs cents.

The second hole is overweight holders. Aggressive, you said someone at 1.5x has six slices to sell, but the plan only schedules three: one now and two on rungs or the clock. The other three have no date. Nothing in this debate gave a reason to carry exposure above a standard allocation into a no-edge setup with gap history. I'd sell the excess above 1.0x with the first order and then run the sixths on the schedule.

Third, the price cancel is overriding the fundamentals. As Aggressive wrote it, a weekly close over 37.59 cancels the clock and any extra sixth, including one a failed hold test or a dividend tripwire would trigger. Neutral wrote it as a pause, and I prefer that, tightened. Price can stop the rungs and the clock, but it can't cancel a fundamental tripwire. A dividend cut after a rally is the same news at a higher price. A weekly close over 37.59 only clears the 50 SMA, and the weekly SuperTrend is still at 42.88.

Fourth, the rebuy test is the hold test's mirror image. We just agreed a hold test that passes on "outlook fits $1.68" is a test nobody can fail, because the price already reflects that. The rebuy test has the same flaw. Revenue declining by less than 4.3% is a thin bar, since -4.2% clears it. Gross margin up year over year is also easy when Q2 FY26's 40.6% was the second-weakest quarter in the table. "Outlook not cut" is just the status quo. The rebuy should require something the price doesn't already assume, such as forward EPS moving up after the print or an outlook that sits above $1.68. Keep the two-sixth cap. You'd be buying after the gap, so the cost of having trimmed is already accepted, and the print has to earn the shares back.

Two smaller points, Aggressive.

You said a reclassification big enough to lift Q4 would show up in Q1's 42.8%, and I wouldn't lean on that. If the 10-K recast the whole year, derived Q4 absorbs the entire recast, because Q1 through Q3 are as originally reported. Q1 FY27 would then sit on the new basis. Depending on how the prior-year figure was pulled, 42.8% could be a decline against a recast base and not a 60 basis point gain. I'm not saying that happened. I'm saying the filing settles it in a line, and you've already agreed the 60 basis points stays out of the reasoning until then.

Your closing line also brings back a half-sized position "I can afford to be wrong on." That is "survivable" again, which Neutral already took apart. A repeat of the 15.5% gap costs about 7.8% of an allocation at a half. Whether that's affordable depends on a book none of us can see. The half is only affordable if the standard allocation was, and that's why the third is a rule and not a feeling.

I'm still at Sell as a trim, with the plan you've both built. I'd add four edits: a first order that actually fills, the excess over a standard allocation sold up front, price unable to cancel a fundamental tripwire, and a rebuy keyed to a change from the $1.68 the price already reflects. The base stays at a half and the floor at a third. If you hold no NKE, this just means don't buy here.

Neutral Analyst¶

Neutral Analyst: You two are arguing over about a dollar ten of price and a few weeks of path, and that hides the fact that you're leaning on the same shaky pillar, which is gap risk. I'll take the pieces in order.

First, what we all agree on. The research plan puts expected value at roughly -1% to +4%, which is cash. Nobody here has an edge big enough to justify a hard swing either way, so this is a variance and information decision. Today's tape also isn't a place for a decisive move. Price sits at the Bollinger midline, the daily z-score is -0.06, and the weekly and monthly TD-9s are complete. It's neither stretched high nor washed low, so I'd build a modest trim that works in most paths rather than a bet on one.

Aggressive, your 3.7 to 1 rests on 31.97, a single intraday low. Every other downside marker in the evidence clusters near 34: HSBC's new target, the lower band at 33.82, and the October 2 closing low at 33.87. You already concede it's about 2 to 1 on 33.85, and I'd make that your headline number. At market it's about 0.6 to 1, with 1.45 of downside against 2.29 of risk. The ratio also assumes a fill. Treat the next few weeks as a driftless random walk (my own back-of-envelope, not in any report) and the stock tags 36.4 before 33.82 only about 57% of the time. Roughly four times in ten the ladder never fills and you're holding the full position at the lower band, and your own negative-drift thesis makes that worse. Conservative is right that a limit ladder is path-dependent. "Cheap option" is also the wrong phrase for a stock with no floor. And "stocks rarely bottom while targets are being cut" cuts both ways, because price tends to turn before revisions do. HSBC's $34 is only about 4% under spot, which is hardly a collapse call.

Conservative, you overstate the cost of the first slice. 1.5% is the cost of selling the entire half at market instead of at 36.4, and only if the ladder fills. Front-loading a third to half of the trim costs more like 0.5% to 0.8%, and in the roughly 40% of paths where price breaks down first, that same slice saves about as much. That's near zero in expected value with lower variance, which is the right way to defend it. But you don't have to sell at market to get it. A first rung at 35.8 to 36.0 sits inside the old 35.5 to 36.4 closing cluster and is under a 2% move, about half an ATR. By the same math it fills about seven times in ten before the lower band is touched. On a one-third slice it costs about a quarter percent of a standard allocation versus 36.4, instead of about half a percent at market.

Your other costs are mostly noise. The stock marks down by roughly $0.41 on the ex-date, so selling ahead doesn't forfeit the dividend in total-return terms. Nineteen million shares at $35 is about $680 million a day, so thin tape matters to nobody sizing a normal position. FOMC, CPI and the midterms move the whole market, and NKE's beta is 1.10. The 7% to 15% single-day gaps weren't macro.

Neither of you has noticed that the three big gaps line up with Nike's reporting cadence: December 18 to 19, March 31 to April 1, and October 1 to 2. The tools don't attribute them to earnings, so that's my inference. But the Q1 FY27 numbers are already in the filings, which fits October 2 being the reaction. If so, gap risk isn't a continuous hazard over the next six weeks. The next scheduled one is probably mid-to-late December, after the Dec 1 finish. Aggressive, "waiting means taking another gap" mostly doesn't apply to this window, and the real reason to be done by December is the earnings date. Conservative, that also takes the urgency out of the options hedge. A collar caps upside on a stock with two completed higher-tier buy setups, so I'd revisit it only if a large retained piece is still there heading into December. Unscheduled risk isn't zero, since the August 17 break on 58.7M shares wasn't a report date, but it's a different size.

Splitting the trim into thirds also answers Conservative's complaint about the deadline. Only the last third, about a sixth of the original position, would ever be sold into weakness on Dec 1.

On the bridge, it's neither something to wait on nor something to skip. The 10-K and 10-Q are public and the read takes an afternoon. The same filings carry inventory, segment and Greater China detail, and debt, which our fundamentals tool lacks. Guidance is the one piece that isn't there. I'd read them this week and size within 0.4 to 0.6x from there: durable gross margin leans toward 0.6, a one-off toward 0.4 or lower. Aggressive, the market is already at 21x forward EPS of $1.68, so "clean EPS" isn't news the price is ignoring. The real question is whether $1.68 is too low or about right. "Down 80% from the high" is an anchor, but so is the bull math. At FY24's $3.73 of EPS the stock would be under 10x. Neither is a forecast.

On triggers, Conservative is right that 31.97 is too far. But a close under the 33.82 band is only about 1.4 ATR from here, and the stock closed at 33.87 eight sessions ago. If that automatically cut the retained position again, ordinary noise would whipsaw you. I'd want a close below the October 2 closing low with volume picking up, or a second close, and then cut toward 0.25 to 0.3x. On the upside, a weekly close above 37.59 with RSI over 50 and OBV confirming means stop trimming and don't chase.

So I back the Sell as a trim, in three equal pieces. The first goes around 35.8 to 36.0, the second at 36.4 to 36.9 (the daily SuperTrend flip and the upper band), and the third at 37.2 to 37.6 (up to the 50 SMA). The working target is 0.5x of a standard allocation until the filings are read, since I don't know the actual position. Add no new money at 35.30, and finish stragglers by Dec 1. With the ten-year having peaked at 5.31% and hike odds at 82%, I'd park proceeds in bills rather than long bonds. Neutral Analyst: We've converged more than the tone suggests. Trim in sixths, rungs near 36.4 to 36.9 and 37.2 to 37.6, no new money, proceeds in bills, stop selling on a weekly close over 37.59 with RSI and OBV confirming. What's left is the first slice, how the downside triggers are built, and what to do about December.

Conservative, you're right on the first slice. My "seven in ten" was a fill probability, not an edge. On a driftless walk, a resting order at 35.9 and a sale now have the same expected outcome: about 0.3% of allocation better on the sixth if it fills, about 0.7% worse if the lower band comes first. And the history isn't driftless. Your arithmetic actually understates your case. The three gaps compound to about -27%, but the stock is down 51%, so the ordinary days did the rest, about -33%. That's closer to half the decline than a third. It also undercuts my claim that gap risk is mostly scheduled and so the next six weeks are quiet. So I'll give you the first sixth now. It costs nothing in expectation, and it means you're never at full size when a breakdown comes.

But your trigger design has a sizing problem. "First close under 33.85 takes you to about 0.4x" sounds like one sixth, and it isn't. If only the first sixth has been sold, you're at about 0.83x, and getting to 0.4x means selling roughly 0.43 of the position at the next open after a single close. If the stock bounces back to 35.30 the next day, that whipsaw costs about 2% of allocation, which is the same order as being late. So make the triggers slices, not targets. The first close under 33.85 sells one sixth, and a second close or an expanding-volume close sells another. Either door lands you near 0.5x: up through the rungs, or down through the triggers. Going to 0.3x would take a close under 33.82 on heavy volume, or a bad filing. Your own list also has an inconsistency, because three sixths leave you at 0.5x, not the 0.4x you list as the target. The extra tenth should be what the filings buy, not a default.

On December, you're right that the retained half rides into the print by design, and that's the main risk left. But a 10% move on a half being "more than the plan's whole upside" compares a tail to an expected value, and the tail has two sides. All we know is that the last three were down. That's a reason to care about variance, not a forecast. So price the January put spread this week, since a quote commits nobody, and set the rule now. If the filings are clean and the quote is fair, hold the half through the print. If the filings are murky or the quote is rich, sell one more sixth before the print instead of paying an event premium. Selling has a known price, and an option I haven't seen doesn't.

On free cash flow, your subtraction is right: Q4 FY26 was about $1.5B. But FY25's Q4 was only about $363M ($3.27B for the year minus $2.9B through nine months). So a big Q4 isn't a stable seasonal pattern, and the odd quarter looks like the same one with the 49% gross margin. The filings that explain one probably explain the other. I agree the dividend isn't a cushion, and the CFO change belongs on the reading list, since an 8-K check takes minutes. But $6.9B of cash against a $2.4B payout doesn't move me from 0.5x to 0.4x on its own.

Aggressive, your point that Q1 FY27 already shows the run rate, with gross margin at 42.8% and EPS in line with the $1.68 forward number, is good. It makes the 0.6x branch much less likely, so I'd now call the realistic range 0.4 to 0.5x. But I wouldn't say the filing will be read before the upper rungs could fill. One ATR day gets the stock to 36.4. So sell the first sixth now, read the filings in the next day or two, and then rest the other two rungs. Your buyback idea also needs its rule written in advance, meaning what margin and revenue prints would make you rebuy. And if December gaps up, you rebuy higher, which is the price of trimming.

The plan, then: sell the first sixth now, rest the other two rungs after the filing read, and sell downside slices on the first and second closes under 33.85. Aim for 0.5x as the working target, with 0.4x only if the filings say so. Price the put spread this week and decide before the print. Add nothing at 35.30, and keep proceeds in bills. All of this is relative to a standard allocation, and if you hold nothing, it means don't buy here. Neutral Analyst: We're down to a few real disagreements, so I'll start with a correction to something I introduced myself.

I've been quoting fill probabilities as if they favored one order type. On a driftless walk, every one of these orders is a fair bet. A sixth sold at 36.65 gains about 0.6% of an allocation over selling at 35.30, and it fills a bit over half the time. If the lower band comes first, that sixth sells about 0.7% worse. Probability times payoff nets to roughly zero. The same is true of the 37.4 rung, which fills less often but pays more when it does. So Conservative, "the rungs fill less often" isn't an argument against them. Aggressive, the rungs aren't a discount either. Orders only change the shape of the path, so the better question is what size we want at each date that matters. Also, I don't hold a negative tilt, whatever you attribute to all three of us. Mine is no drift, fat tails, and two completed higher-tier TD-9s I won't ignore. Negative drift says sell now, mean reversion says rest the rungs, and I don't know which, so I spread across both.

Conservative is right that the two doors need one budget. Aggressive's "either way I end near 0.5x" only holds if each sixth is sold once. A rally that fills a rung and then reverses through 33.85 could walk us down to 0.17x. So the base case is three sixths in total across both doors, and everything else cancels once the third is gone. A fourth sixth needs a bad read of the filings or a heavy-volume close under 33.82, and the floor is a third.

Conservative's worry about waiting for a rally deserves a fix that doesn't front-load. I'd add a clock. If neither door has opened by mid-November, after CPI and the dividend declaration, the second sixth goes at market. The third gets the same treatment by December 1. That way the deadline isn't one dump into the ex-date.

Here is where I push back hardest, Conservative. You'd sell the next sixth at market if the filings call Q4's 49.2% gross margin a one-off. But Q1 already printed 42.8%, forward EPS is $1.68, and the stock trades at 21x that. Even clean trailing EPS of about $1.75 to $1.80 is above what the market is capitalizing. The price is already on the one-off branch. I called the bridge the cheapest unknown to resolve, and I'd now call it the least valuable. It can only surprise in the direction we're not leaning, a durable explanation. That means I'd drop the trader's "cut to 0.25x on a one-time gain" trigger. What can move size is elsewhere in the same documents:

The outlook language.
Inventory and working capital behind operating cash flow of $135M versus $222M on flat earnings.
Any change in dividend wording.
The reason for the CFO change.

If those read badly, sell the next sixth at market that day. If they read clean, let the doors and the clock work.

On December, you win the outlook point. "Filings clean" looked backward. The test for holding the half through the print should be an outlook in the Q1 release and call that's consistent with $1.68, an unchanged dividend declaration, and a January put spread quote I can live with. Price it this week and decide in the first half of November, not when event premium is fattest. I'll accept a version of your flipped default: if I can't write one sentence on why the retained sixth earns its variance, it goes. But the sentence doesn't need an edge. "Outlook fits $1.68, the price reflects it, and this is the piece that participates if December gaps up" is enough. Your logic that we have no edge, so variance is unrewarded, argues for zero, and you've said you don't want zero. We've also all said the expected value is about cash without stating a horizon. A range of -1% to +4% midpoints at 1.5%, which is under bills over a year and a touch above over a quarter. That number is soft, so hold it loosely in both directions.

On gaps, your arithmetic is right. Repeating the 10.5% gap at 0.83x costs about 8.7% of an allocation, and sizing is the only real gap protection. But that's a percentage of the allocation, not of the book. At an allocation of a few percent, it's a few tenths of a percent of the portfolio. That's a reason to size sensibly, not to rush the next sixths at market.

Aggressive, the rebuy rule needed Conservative's fix, but his fix has a seasonality problem. Gross margin ran 42.2%, 40.6% and 40.2% across Q1 to Q3 FY26, then 42.8% in Q1 FY27. Q2 FY26 was 40.6%, so requiring 42.8% in Q2 FY27 asks for a 220 basis point jump just to get you back in. Compare each quarter with its prior-year quarter instead:

Gross margin up year over year, as Q1's was by 60 basis points.
A revenue decline narrower than 4.3%.
Positive free cash flow. Q2 and Q3 FY26 together produced about $670M, so that isn't an unreasonable bar.

The plan, sized against a standard allocation since we don't know the book:

Sell the first sixth now and add nothing at 35.30.
Read the 10-K, 10-Q, Q1 release and call this week for outlook, inventory and working capital, dividend wording and the CFO change. A bad read means the next sixth goes at market. A clean read means resting the second sixth at 36.4 to 36.9 and the third at 37.2 to 37.6.
Downside slices fire on the first close under 33.85 and on a second close or an expanding-volume close, all under one budget.
The clock sells the second sixth by mid-November and the third by December 1, and proceeds go to bills.
Stop selling on a weekly close over 37.59 with RSI above 50 and OBV confirming.
Before the print, sell one more sixth unless the outlook and the put quote support holding the half.

If you hold nothing, this just means don't buy NKE here. Neutral Analyst: We're down to a few loose ends, so I'll take what I'm taking and spend the time on where each of you still has a hole.

Conservative, you're right that our hold test couldn't be failed. If $1.68 came out of the outlook, the outlook will match $1.68. So I'll write today's forward EPS down now and make the fail condition a drop from it by the decision date. I'd put a tolerance on that, because a one or two cent wobble in a vendor's number after a target cut isn't information. A few percent below $1.68 fails, which is my judgment and not a derived threshold. I also accept that a pass means you actually buy the spread. Your caution that the 49.2% margin is derived, and that the 60 basis point year-over-year gain may not be like for like, belongs on the reading list. So does the two-sixth cap on any single rebuy, since one print is one observation.

Aggressive, you're right that the base is a half and the floor a third, and that the rebuy compares each quarter with its prior-year quarter. I'd tighten that rebuy test to say "like for like as the filing presents it."

Now the holes. Conservative, you changed the unit. The trader's plan is half of a standard allocation, but your final plan says sixths of whatever you hold now. Those only match if the holding equals a standard allocation. An overweight holder who sells three sixths of their own position is still well above half. An underweight holder who does it ends up far below. Size each slice as a sixth of a standard allocation. If you're already at or under half, sell nothing and just keep the downside triggers.

I also think "buy the spread or sell a sixth" needs a practical caveat. Options trade in 100-share lots, and the retained half of a small position may be too small for a clean spread. Selling is the cleaner tool there.

Aggressive, the June check is a good prompt, but it's carrying more weight than it can. We don't have the report date. The slide from 46.18 on June 12 to the 40.32 close on June 26 includes two weeks of ordinary drift, and if the print came after that close, the reaction isn't in the number at all. Conservative then turned it into "the market has sold four prints." That's a pattern built on prices nobody has tied to a date. If it is a real reaction, it says the market looked through a 49% margin, which is what we agreed when we retired the bridge trigger. Check the date, and until then don't count it.

I'd also push back on "survivable." A repeat of the 15.5% gap costs about 7.8% of an allocation at a half. That's trivial for a small slice of a diversified book and not trivial for a concentrated one, and we don't know which this is. That's why the third is a rule and not a feeling.

Here's a timing problem you both missed. The hold test has a dividend leg, but the declaration ahead of the December 1 ex-date probably lands in mid-to-late November, after the early-November hedge decision. That date isn't in our evidence. So split the test. In the first half of November, check forward EPS against today's number, check the outlook, and price and buy the spread if the quote is inside your pre-set cap. The dividend is a tripwire. If the declaration is cut or hedged, a sixth goes that day, and being a bit over-hedged afterward is a small cost. Our evidence only shows $0.41 on four straight ex-dates, not the raise history, so I can't say whether flat is a quiet pass or a break from habit. Add that to the reading list.

On the cancel trigger, a weekly close above 37.59 with RSI over 50 and OBV confirming stops the clock. That's a pause in selling, not a reason to rebuild. The weekly SuperTrend would still be down until 42.88, so higher tiers still outrank the bounce. A close below the 31.97 low is also not a mechanical sell. It's the point where we throw the plan away and re-underwrite it.

So the final plan, with sizes relative to a standard allocation:

Sell the first sixth at today's open, with a marketable limit near the 35.30 close, and add nothing.
This week, read the 10-K, 10-Q, Q1 release and call for outlook, inventory and working capital behind the $135M of operating cash flow, dividend wording, the CFO change, and the margin comparison. A bad read sells the next sixth that day.
A clean read rests the second sixth at 36.4 to 36.9 and the third at 37.2 to 37.6.
Downside slices sell a sixth on the first close under 33.85 and another on a second close or an expanding-volume close, all under one budget. The clock sells the second sixth by mid-November and the third by December 1.
Run the hold test as split above, and sell one more sixth if any leg fails.
Proceeds go to bills.

The base is half, the floor is a third, and the floor moves only on a new fact.

You each get something real. Aggressive gets variance reduction without a forced exit, and cash that can be redeployed under a written rebuy rule. Conservative gets front-loading, a hedge with a price cap, and a floor. Nobody pays for a view we can't back with an edge. I don't know your book, so if you hold none, this just means don't buy NKE here. Neutral Analyst: We're down to execution details, so I'll go through what I'm taking from each of you, where each of you is still off, and then put the plan in one place.

Conservative, you're right about the first order. A sell limit at 35.30 only fills if the bid is at or above 35.30. If NKE opens at 34.80, it sits there, and that's the resting-above-the-market behavior we spent three rounds removing. I'd go one step past "just use a market order," though. This stock opened 7.4% below its prior close on October 2, so I wouldn't send a market order into the opening print either. Enter it once the opening range settles, with a limit a few cents through the live bid. A 19M-share day is plenty of depth for a normal size.

You're also right about the excess over a standard allocation. Aggressive, your six slices for someone at 1.5x had three with no date, and nothing in this debate argues for carrying more than a standard allocation into a no-edge setup with this gap history. That's a sizing rule, not a view on NKE, so sell the excess with the first order. If it's a meaningful fraction of a normal day's volume, work it over a few sessions.

And you're right that price can pause the rungs and the clock but can't cancel a fundamental tripwire. A dividend cut after a rally is the same news at a higher price.

On the rebuy, I agree with the principle. A test that passes on "outlook not cut" buys back the risk you just sold. But the forward-EPS tolerance I wrote for the hold test applies in the other direction too. A vendor number that moves a few cents isn't information, so the rebuy needs forward EPS up by more than that wobble, or a guide above $1.68, plus the like-for-like margin, a narrower revenue decline and positive free cash flow. Keep the two-sixth cap after any one print. We're writing a December rule in October, so write it down and stop polishing it. The cost is that you'll probably rebuy above where you sold, and that's the price of having trimmed.

Aggressive, you're still too comfortable in a few places. "A half-sized position I can afford to be wrong on" only holds if the standard allocation was affordable. A repeat of the 15.5% gap on a half is about 7.8% of an allocation, and whether that matters depends on a book none of us can see. "The cash is the option" has the same condition: it's only an option if the rebuy rule is real. Conservative also has the reclassification point right. If the 10-K recast the year, derived Q4 absorbs the whole recast while Q1 FY27 sits on the new basis. Then the 60 basis point gain could be a decline, and your argument that a reclassification would show up in Q1's 42.8% doesn't hold. I still think the bridge can't move size, because the price already assumes the one-off branch. But the like-for-like line stays on the reading list because the rebuy rule leans on it.

Conservative, you keep finding real holes, but each round has also added another reason to sell earlier or more. The plan now has a first sixth today, an excess sale, a bad-read pull-forward, a clock, two downside slices, a hold test and a dividend tripwire. That's enough front-loading. I wouldn't add more without a new fact. The hold test already fails closed, and if any leg is unclear, the sixth goes. I'd also resist treating every missing number as grounds to cut. The filings can move size only through the items we listed, and a clean read should let the rungs and the clock do their work.

The last point is one nobody has made. Everything here is relative to a standard allocation, and for a small allocation in a diversified book, the rung levels and the 33.85 triggers are rounding error. The parts that matter are the level (a half, with a floor of a third), the excess sale, and the written tests. If the position is concentrated, go toward the floor sooner. I'd also anchor the clock to the confirmed report date and not to December 1. The date isn't in our evidence, and if it's earlier than late December, everything moves earlier with it.

Here's the plan:

Today: Sell the excess over a standard allocation plus the first sixth, with a limit a few cents through the live bid after the open settles. Add no new money.
This week: Confirm the report date. Read the 10-K, 10-Q, Q1 release and call for the outlook, inventory and working capital behind the $135M of operating cash flow, dividend wording, the CFO change, and whether the margin comparison is like for like.
Read result: A bad read pulls the second sixth forward at market. A clean read rests the second at 36.4 to 36.9 and the third at 37.2 to 37.6.
Budget: There is one budget. Three sixths take you to a half, and each sixth is sold once, whichever of the rungs, the clock, the first and second closes under 33.85, or the read gets there first. The clock sells the second by mid-November and the third by December 1, or earlier if the report date is earlier.
Hold test: In the first half of November, check forward EPS against the written-down $1.68 with a tolerance, and check the outlook. If the quote is inside a cap set before looking and the size supports it, buy the spread. A failed leg sells the fourth sixth, to a third.
Dividend: A cut or hedged wording sells a sixth that day.
Price signals: A weekly close over 37.59 with RSI above 50 and OBV confirming pauses the rungs and the clock, but not the tripwires. A close under 31.97 means throw the plan out and re-underwrite.
Proceeds: Proceeds go to bills.

It's still a Sell, as a trim, with a half as the base and a third as the floor. If you hold no NKE, it just means don't buy here.

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Underweight

Executive Summary: Underweight NKE. Cut exposure to about 0.5x a standard allocation, with a floor of 0.33x, selling in slices of one-sixth of a standard allocation and adding no new money at $35.30. If you hold none, don't buy. Today, once the open settles, sell any excess above 1.0x plus the first sixth, using a limit a few cents through the live bid. After reading the 10-K, 10-Q, Q1 release and call this week, rest the second sixth at 36.4-36.9 and the third at 37.2-37.6. A clock forces those out by mid-November and Dec 1, or earlier if the confirmed Q2 report date is earlier. Also sell one sixth on each of the first and second closes below 33.85; all of these count against a single three-sixth budget. A weekly close above 37.59 with RSI above 50 and OBV confirming pauses the selling but never cancels the fundamental tripwires. A failed early-November hold test or a dividend cut takes you to the 0.33x floor, and a close below 31.97 forces a full re-underwrite. Horizon is 3-6 months, through the late-December Q2 FY27 print and one more quarter, with proceeds held in T-bills.

Investment Thesis: RATING MAPPING. The Research Manager's Underweight and the trader's Sell describe the same action: a trim, not an exit or short. All three risk analysts finished at a trim to about half a standard allocation. On this scale that is Underweight, since Sell means exit or avoid. The case for reducing wins clearly. The case for going to zero does not.

WHY REDUCE. (1) Expected value is about the same as cash. The research trees give -1% to +4% total return. That is close to the bill yield and well short of an 8-9% hurdle, and the 4.6% dividend is already inside that figure. The majority branch, at 55-60%, is that Q4 FY26 was a one-off. Derived Q4 gross margin was 49.2% against 40-43% in every adjacent quarter, and net income was $1.07B against roughly $675M for the other TTM quarters. Q1 FY27 printed 42.8% gross margin and $712M of net income, in line with forward EPS of $1.68. That puts NKE at about 21x forward earnings while revenue growth has decelerated five straight quarters to -4.3%, and revenue sits 10% below the FY24 peak. (2) Cash flow is weaker than earnings. About $1.5B of FY26's $2.18B FCF came in Q4 alone ($2,184M minus $685M for nine months), versus about $363M in Q4 FY25. Excluding Q4, the run rate is under $1B a year against a payout of about $2.4B. Q1 FY27 operating cash flow was $135M versus $222M a year earlier, and FCF was -$64M. A yield below the 5.21% 10-year is not a cushion. (3) The technicals agree. SuperTrend is down on the daily (36.38), weekly (42.88) and monthly (59.28) tiers. Price is 6.1% below the 50 SMA and 24.7% below the 200 SMA, and the 50 sits under the 200. RSI is 43.82. OBV has been flat near -1.631B while price rose about 3.9%, and volume of 19.4M is the lowest since 08-24. That reads as a relief bounce, not accumulation. (4) Gap and drift risk. Past gaps were -10.5%, -15.5%, and a 7.4% open gap on 10-02 (-3.6% close to close), so stops will not protect. The Conservative analyst's decomposition matters here: the gaps compound to about -27% of the roughly -51% decline, so ordinary drift did about half the damage. On macro, per the research debate, the 10-year is at 5.21% (peaking at 5.31%), odds of a hike are about 82%, and the FOMC, the Nov 3 midterms and CPI all come before Q2.

WHY NOT SELL. There is no solvency issue: $6.9B of cash, a 2.07 current ratio and 0.73x D/E. Weekly and monthly TD-9 buy setups are complete, and the weekly and monthly z-scores are -1.30 and -1.56. Q1 gross margin rose 60 bp year over year, pending confirmation that the comparison is like for like. Insiders bought about $9.2M at $42-62, though they are underwater and none has bought since April. Nobody showed an edge for being fully out, and at 21x $1.68 the price already assumes the one-off branch.

DEBATE ADJUDICATION. Conservative won these points: sell the first sixth now rather than resting it at 35.8-36.0, because on a driftless walk the rung is a wash and our negative tilt breaks the tie. The first order must actually be marketable. Excess above 1.0x goes up front. Price signals can pause the plan but not cancel fundamental tripwires. Any rebuy must require a change from the $1.68 the price already reflects. Neutral won these points: triggers should be sixth-sized slices under one budget, which avoids a roughly 2% whipsaw from forcing 0.43x out on a single close. A clock beats waiting for a rally. The Q4 bridge alone cannot move size. Rebuy margin tests must be year over year, since Q2 FY26 gross margin was 40.6%. The clock should anchor to the confirmed report date. Aggressive held two points: 0.5x is the base and 0.33x the floor, and he properly withdrew his 3.7:1 claim (about 2:1 from 36.4 to 33.85). I reject more front-loading unless a new fact appears.

PRICE TARGET: $33.60, a valuation objective. Forward EPS of $1.68 x 20x = $33.60. I use 20x, one turn below today's roughly 21x, which is the top of the 17-20x bad-branch range both research sides called arguable. It also reflects multiple compression on a shrinking-revenue turnaround with the 10-year above 5%. That is about 4.8% below 35.30. Adding about $0.82 of dividends over six months gives roughly -2.5% total return, consistent with expected value below the hurdle. Cross-checks: the lower Bollinger band at 33.82, the 10-02 closing low at 33.87, and the HSBC $34 target cited in the debate. The bear branch (clean EPS of $1.75-1.80 at 15-18x) gives $26-32. The bull half-recovery gives $42-46.

WHAT CHANGES IT. Upgrade to Hold, then rebuild, buying back at most two sixths after any one print and the rest only after a second confirming quarter, if all of these hold: forward EPS rises beyond vendor noise or guidance comes in above $1.68; gross margin is up year over year on a like-for-like basis; the revenue decline is narrower than -4.3%; and FCF is positive without a Q4-style working-capital swing. Defer any rebuy while the 10-year holds above 5.31%. A weekly close above 37.59 only pauses selling. A trend flip needs a weekly close above 42.88. Go to the 0.33x floor on any of these: an early-November hold-test failure (forward EPS a few percent below $1.68, a weak outlook, or a put-spread quote above a cap set in advance; if the position is too small for 100-share lots, sell instead); dividend wording that is cut or hedged (a flat $0.41 passes); or a bad read on inventory and working capital, the outlook, or the Friend-to-Denton CFO change. A close below 31.97 means re-underwrite, likely to Sell.

DATA GAPS. Missing: the Q4 FY26 bridge and whether the margin comparison is like for like, guidance, inventory, segment and China detail, debt and lease detail, the Q2 report date, the dividend declaration date (the ~12/01 ex-date is inferred), option prices, and bill yields. The macro data and the broker actions come from the debate, not the reports.

Current Price: 35.3

Price Target: 33.6

Confidence: Medium

Time Horizon: 3-6 months